

# Vietnam

# **Country Operational Plan**

# FY 2014

Note: Italicized sections of narrative text indicate that the content was not submitted in the Lite COP year, but was derived from the previous Full COP year. This includes data in Technical Area Narratives, and Mechanism Overview and Budget Code narratives from continued mechanisms.



## **Budget Summary Reports**

#### Summary of Planned Funding by Agency and Funding Source

		Funding Source				
Agency	GAP	GHP-State	GHP-USAID	Total		
HHS/CDC	1,857,750	14,644,314	0	16,502,064		
HHS/HRSA		214,000		214,000		
HHS/SAMHSA		1,200,000		1,200,000		
USAID		30,668,408		30,668,408		
Total	1,857,750	46,726,722	0	48,584,472		

## Summary of Planned Funding by Budget Code and Agency

				Age	ncy	-				
Budget Code	State	State/EA P	DOD	HHS/CDC	HHS/HRS A	HHS/SAM HSA	USAID	AllOther	On Hold Amount	Total
НВНС			0	1,809,429			1,178,718		0	2,988,147
HKID				85,227					0	85,227
HLAB			0	2,342,753					0	2,342,753
HMBL			0							0
HMIN			0						0	0
HTXD							10,600,00 0		0	10,600,00 0
HTXS			0	4,220,097	14,000	150,000	3,930,940		0	8,315,037
нуст			0	1,804,961			1,487,833		0	3,292,794
H∨MS	0		0	0		414,000	2,465,708		0	2,879,708
HVOP		0	0	360,358			2,618,559		0	2,978,917
HVSI			0	1,712,940	200,000		1,313,615		0	3,226,555
нутв			0	1,074,134			1,020,001		0	2,094,135
IDUP				684,291		636,000	3,470,428		0	4,790,719
МТСТ			0	737,488					0	737,488
OHSS			0	948,782			2,542,604		0	3,491,386



PDCS				182,389			0		0	182,389
PDTX				539,215			40,002		0	579,217
				16,502,06			30,668,40			48,584,47
	0	0	0	4	214,000	1,200,000	8	0	0	2

Approved



### **Budgetary Requirements Worksheet**

Redacted

## **Technical Areas**

## **Technical Area Summary**

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	2,758,123	0
НКІД	85,227	0
НУТВ	2,074,134	0
PDCS	182,389	0
Total Technical Area Planned Funding:	5,099,873	0

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	2,342,753	0
HVSI	2,861,515	0
OHSS	3,228,857	0
Total Technical Area Planned Funding:	8,433,125	0

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HMIN	0	0
НУСТ	3,282,794	0
HVOP	2,688,884	0
IDUP	4,264,694	0



МТСТ	737,488	0
Total Technical Area Planned Funding:	10,973,860	0

#### Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
НТХД	10,600,000	0
HTXS	7,881,991	0
PDTX	539,215	0
Total Technical Area Planned Funding:	19,021,206	0



## **Technical Area Summary Indicators and Targets**

Indicator Number	Label	2014	2015
	Number of unique sites supported by PEPFAR	1,780	1,780
	By program area/support type: HTC Direct Service Delivery (DSD)	127	116
	By program area/support type: HTC Technical Assistance-only (TA)	4	24
	By program area/support type: Treatment Direct Service Delivery (DSD)	102	102
	By program area/support type: Treatment Technical Assistance-only (TA)	27	27
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	102	102
	By program area/support type: Care and Support Technical Assistance-only (TA)	27	27
	By program area/support type: Food and Nutrition Direct Service Delivery (DSD)		
	By program area/support type: Food and Nutrition Technical Assistance-only (TA)		



	ŀ	
By program area/suppo type: PMTCT Direct Ser Delivery (DSD)		63
By program area/suppo type: PMTCT Technical Assistance-only (TA)	t 11	49
By program area/support type: TB/HIV Direct Serv Delivery (DSD)		
By program area/suppo type: TB/HIV Technical Assistance-only (TA)	ť	
By program area/suppo type: VMMC Direct Serv Delivery (DSD)		
By program area/suppo type: VMMC Technical Assistance-only (TA)	t	
By program area/support type: General Population Prevention Direct Service Delivery (DSD)	n	
By program area/support type: General Population Prevention Technical Assistance-only (TA)		
By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	91	10 <sup>,</sup>
By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	t 101	124
By program area/suppo	t	



	type: OVC Direct Service		
	Delivery (DSD)		
	By program area/support		
	type: OVC Technical		
	Assistance-only (TA)		
	By program area/support		
	type: PHDP/Family Planning		
	& Integration Direct Service		
	Delivery (DSD)		
	By program area/support		
	type: PHDP/Family Planning		
	& Integration Technical		
	Assistance-only (TA)		
	By program area/support		
	type: Lab Direct Service	80	66
	Delivery (DSD)		
	By program area/support		
	type: Lab Technical	1,208	1,561
	Assistance-only (TA)	,	,
	PMTCT_SITE Percentage of		
	PEPFAR-supported sites		
	achieving 90% ARV or ART	n/a	
	coverage for HIV+ pregnant	n/a	
	women		
	Number of		
	PEPFAR-supported sites		
	achieving 90% ARV or ART		56
PMTCT_SITE	coverage for HIV+ pregnant		50
	women		
	Total number of PEPFAR		
	supported sites providing		70
	PMTCT services (HTC and		
	ARV or ART services)		
	By site support type: Direct		46
	Service Delivery (DSD):		10



	Number of PEPFAR-supported sites		
	achieving 90% ARV or ART		
	coverage for HIV+ pregnant		
	women		
	By site support type:		
	Technical Assistance-only		
	(TA): Number of		
	PEPFAR-supported sites		10
	achieving 90% ARV or ART		
	coverage for HIV+ pregnant		
	women		
	Sum of Numerator Support		
	Type disaggregates		56
	By site support type: Direct		
	Service Delivery (DSD):		
	Total number of PEPFAR		
	supported sites providing		59
	PMTCT services (HTC and		
	ARV or ART services)		
	By site support type:		
	Technical Assistance-only		
	(TA): Total number of		
	PEPFAR supported sites		11
	providing PMTCT services		
	(HTC and ARV or ART		
	services)		
	Sum of Denominator Support		
	Type disaggregates		70
	PMTCT_STAT_DSD		
	Number and percentage of		
	pregnant women with known	00.04	
PMTCT_STAT_DSD	status (includes women who	99 %	
	were tested for HIV and		
	received their results) (DSD)		
	Number of pregnant women	350,000	293,000



with known HIV status       (includes women who were tested for HIV and received their results)         Number of new ANC and L&D clients       355,000       295,000         By: Known positives at entry       855       775         By: Number of new positives       640       600         identified       1,495       1,375         By: Number of new positives Status       1,495       1,375         Required only for DREAMS       Countries - By Number of new positives: <15       1         Required only for DREAMS       Countries - By Number of new positives: 15-19       1         Required only for DREAMS       Countries - By Number of new positives: 20-24       1         Required only for DREAMS       Countries - By Number of new positives: 25+       1         Required only for DREAMS       Countries - By Number of new positives: 25+       1         Required only for DREAMS       Countries - By Number of new positives: 25+       1         Required only for DREAMS       Countries - By Number of known positives: <15       1         Required only for DREAMS       Countries - By Number of known positives: <15       1         Required only for DREAMS       Countries - By Number of known positives: <15       1         Required only for DREAMS       Countries - By Number of known positives: <15-19       1 <t< th=""><th></th><th></th><th></th></t<>			
tested for HIV and received their results)aNumber of new ANC and L&D clients355,000By: Known positives at entry855By: Number of new positives (identified640Sum of Positives Status disaggregates1,495Countries - By Number of new positives: <15	with known HIV status		
their results)	(includes women who were		
Number of new ANC and L&D clients355,000295,000By: Known positives at entry855775By: Number of new positives identified640600Sum of Positives Status disaggregates1,4951,375Required only for DREAMS Countries - By Number of new positives: <15	tested for HIV and received		
L&D clients355,000295,000By: Known positives at entry855775By: Number of new positives640600identified1,4951,375Required only for DREAMS1,4951,375Countries - By Number of new positives: <15	their results)		
L&D clients4By: Known positives at entry855By: Number of new positives640identified640Sum of Positives Status1,495disaggregates1,375Required only for DREAMS0Countries - By Number of0new positives: <15	Number of new ANC and	355 000	295 000
By: Number of new positives       640       600         identified       1,495       1,375         Sum of Positives Status       1,495       1,375         disaggregates       1,495       1,375         Required only for DREAMS       Countries - By Number of       1         new positives: <15	L&D clients	555,000	295,000
identified640600Sum of Positives Status disaggregates1,4951,375Required only for DREAMS Countries - By Number of new positives: <15	By: Known positives at entry	855	775
identified       1,495         Sum of Positives Status       1,495         disaggregates       1,375         Required only for DREAMS       1,375         Countries - By Number of       1         new positives: <15	By: Number of new positives	6.40	<b>600</b>
disaggregates1,4951,375Required only for DREAMSCountries - By Number ofnew positives: <15	identified	640	600
disaggregates       A         Required only for DREAMS       Countries - By Number of         new positives: <15	Sum of Positives Status	4 405	4.075
Countries - By Number of new positives: <15 Required only for DREAMS Countries - By Number of new positives: 15-19 Required only for DREAMS Countries - By Number of new positives: 20-24 Required only for DREAMS Countries - By Number of new positives: 25+ Required only for DREAMS Countries - By Number of known positives: <15 Required only for DREAMS Countries - By Number of known positives: 15-19 Required only for DREAMS Countries - By Number of known positives: 15-19 Required only for DREAMS Countries - By Number of known positives: 20-24	disaggregates	1,495	1,375
new positives: <15	Required only for DREAMS		
Required only for DREAMS Countries - By Number of new positives: 15-19Required only for DREAMS Countries - By Number of new positives: 20-24Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	Countries - By Number of		
Countries - By Number of new positives: 15-19Required only for DREAMS Countries - By Number of new positives: 20-24Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	new positives: <15		
new positives: 15-19Required only for DREAMS Countries - By Number of new positives: 20-24Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	Required only for DREAMS		
Required only for DREAMS         Countries - By Number of         new positives: 20-24         Required only for DREAMS         Countries - By Number of         new positives: 25+         Required only for DREAMS         Countries - By Number of         new positives: 25+         Required only for DREAMS         Countries - By Number of         known positives: <15	Countries - By Number of		
Countries - By Number of new positives: 20-24Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	new positives: 15-19		
new positives: 20-24Required only for DREAMSCountries - By Number ofnew positives: 25+Required only for DREAMSCountries - By Number ofknown positives: <15	Required only for DREAMS		
Required only for DREAMS Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	Countries - By Number of		
Countries - By Number of new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	new positives: 20-24		
new positives: 25+Required only for DREAMS Countries - By Number of known positives: <15	Required only for DREAMS		
Required only for DREAMS Countries - By Number of known positives: <15Required only for DREAMS Countries - By Number of known positives: 15-19Required only for DREAMS Countries - By Number of known positives: 20-24	Countries - By Number of		
Countries - By Number of known positives: <15Required only for DREAMS Countries - By Number of known positives: 15-19Required only for DREAMS Countries - By Number of known positives: 20-24	new positives: 25+		
known positives: <15Required only for DREAMSCountries - By Number of known positives: 15-19Required only for DREAMS Countries - By Number of known positives: 20-24	Required only for DREAMS		
Required only for DREAMS         Countries - By Number of         known positives: 15-19         Required only for DREAMS         Countries - By Number of         known positives: 20-24	Countries - By Number of		
Countries - By Number of known positives: 15-19 Required only for DREAMS Countries - By Number of known positives: 20-24	known positives: <15		
known positives: 15-19Required only for DREAMSCountries - By Number ofknown positives: 20-24	Required only for DREAMS		
Required only for DREAMS Countries - By Number of known positives: 20-24	Countries - By Number of		
Countries - By Number of known positives: 20-24	known positives: 15-19		
known positives: 20-24	Required only for DREAMS		
	Countries - By Number of		
Paguirad only for DREAMS	known positives: 20-24		
	Required only for DREAMS		
Countries - By Number of	Countries - By Number of		
known positives: 25+	known positives: 25+		



	Required only for DREAMS Countries - Denominator: <15 Required only for DREAMS Countries - Denominator: <15-19 Required only for DREAMS		
	Countries - Denominator: 20-24 Required only for DREAMS Countries - Denominator:		
	25+ PMTCT_STAT_NGI Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (NGI)	99 %	
PMTCT_STAT_NGI	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	350,000	293,000
	Number of new ANC and L&D clients	355,000	295,000
	By: Known positives at entry	855	775
	By: Number of new positives identified	640	600
	Sum of Positives Status disaggregates	1,495	1,375
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received	92 %	



their results) (TA)		
Number of pregnant women with known HIV status		
(includes women who were tested for HIV and received their results)	35,000	87,000
Number of new ANC and L&D clients	38,000	93,000
By: Known positives at entry	100	222
By: Number of new positives identified	33	88
Sum of Positives Status disaggregates	133	310
Required only for DREAMS countries - By known		
positives: <15		
Required only for DREAMS		
countries - By known positives: 15-19		
Required only for DREAMS		
countries - By known positives: 20-24		
Required only for DREAMS		
countries - By known positives: 25+		
Required only for DREAMS		
countries - By new positives: <15		
Required only for DREAMS		
countries - By new positives: 15-19		
Required only for DREAMS		
countries - By new positives: 20-24		
Required only for DREAMS		



	countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator: 15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	88 %	
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,323	1,235
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,495	1,375
	Life-long ART (including Option B+)	715	978
	Sub-Disag of Life-long ART:	205	510



	Newly initiated on treatment		
	during the current pregnancy		
	Sub-Disag of Life-long ART:		
	Already on treatment at the	510	468
	beginning of the current	510	400
	pregnancy		
	Maternal triple ARV		
	prophylaxis (provided with		
	the intention to stop at the	78	
	end of the breastfeeding		
	period)		
	Maternal AZT (prophylaxis		
	component of WHO Option A		
	during pregnancy and	520	257
	delivery)		
	Single-dose nevirapine (with		
	or without tail)	10	
	Sum of Regimen Type	1,323	1,235
	disaggregates		
	Sum of New and Current	715	978
	disaggregates		
	PMTCT_ARV_NGI		
	Percentage of HIV-positive		
	pregnant women who		
	received antiretrovirals to	88 %	
	reduce risk for		
	mother-to-child-transmission		
PMTCT_ARV_NGI	(MTCT) during pregnancy		
	and delivery (NGI)		
	Number of HIV-positive		
	pregnant women who		
	received antiretrovirals to	1,323	
	reduce risk of	1,323	
	mother-to-child-transmission		
	(MTCT) during pregnancy		



	and delivery		
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,495	
	Life-long ART (including Option B+)	715	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	205	
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	510	
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	78	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	520	
	Single-dose nevirapine (with or without tail)	10	
	Sum of Regimen disaggregates	1,323	
	Sum of New and Current disaggregates	715	
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for	80 %	



mother-to-child-transmission		
(MTCT) during pregnancy		
and delivery (TA)		
lumber of HIV-positive		
pregnant women who		
received antiretrovirals to		
reduce risk of	12	55
nother-to-child-transmission		
MTCT) during pregnancy		
and delivery		
Number of HIV- positive		
pregnant women identified in		
he reporting period	15	65
including known		
HIV-positive at entry)		
Life-long ART (including		
Option B+)		
Sub-Disag of Life-long ART:		
Newly initiated on treatment		
luring the current pregnancy		
ub-Disag of Life-long ART:		
Already on treatment at the		
beginning of the current		
pregnancy		
Maternal triple ARV		
prophylaxis (provided with		
he intention to stop at the		
end of the breastfeeding		
period)		
Maternal AZT (prophylaxis		
component of WHO Option A		
luring pregnancy and		
lelivery)		
Single-dose nevirapine (with		
or without tail)		



	Sum of Regimen Type disaggregates		
	Sum of New and Current disaggregates		
	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	11,500	14,000
	Sex: Male	11,155	13,485
	Sex: Female	345	515
	Sum of Sex disaggregates	11,500	14,000
	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required Total estimated number of	78,626	85,241
	key population in the catchment area By key population type:	26,222	26,030



		L	1
	Female sex workers (FSW)		
	(Numerator: Number of key		
	populations reached with		
	individual and/or small group		
	level HIV preventive		
	interventions that are based		
	on evidence and/or meet the		
	minimum standards required)		
	By key population type:		
	Males who inject drugs (		
	Male PWID) (Numerator:		
	Number of key populations		
	reached with individual		
	and/or small group level HIV	33,083	37,028
	preventive interventions that		
	are based on evidence		
	and/or meet the minimum		
standards required)			
	By key population type:		
	Females who inject drugs		
	(Female PWID) (Numerator:		
	Number of key populations		
	reached with individual		
	and/or small group level HIV	1,021	1,173
	preventive interventions that		
	' are based on evidence		
	and/or meet the minimum		
	standards required)		
	By key population type: Men		
	who have sex with	18,300	
	men/Transgender (MSM/TG)		
	(Numerator: Number of key		
	populations reached with		21,010
	individual and/or small group		
	level HIV preventive		
	interventions that are based		



on evidence and/or meet the	
minimum standards required)	
By key population type:	
MSM/TG who are male sex	
workers (subset MSM/TG)	
(Numerator: Number of key	
populations reached with	
individual and/or small group	
level HIV preventive	
interventions that are based	
on evidence and/or meet the	
minimum standards required)	
By key population type:	
Female sex workers (FSW)	
(Denominator: Total	
` estimated number of key	
population in the catchment	
area)	
By key population type:	
Males who inject drugs (	
Male PWID) (Denominator:	
Total estimated number of	
key population in the	
catchment area)	
By key population type:	
Females who inject drugs	
(Female PWID)	
(Denominator: Total	
estimated number of key	
population in the catchment	
area)	
By key population type: Men	
who have sex with	
men/Transgender (MSM/TG)	
(Denominator: Total	
estimated number of key	
esumated number of key	



	population in the catchment		
	area)		
	By key population type:		
	MSM/TG who are male sex		
	workers (subset MSM/TG)		
	(Denominator: Total		
	estimated number of key		
	population in the catchment		
	area)		
	KP_PREV_TA Percentage of		
	key populations reached with		
	individual and/or small group		
	level HIV preventive	,	
	interventions that are based	n/a	
	on evidence and/or meet the		
	minimum standards required		
	(TA-only)		
	Number of key populations		
	reached with individual		
	and/or small group level HIV		
	preventive interventions that	3,195	5,668
	are based on evidence		
KP_PREV_TA	and/or meet the minimum		
	standards required		
	Total estimated number of		
	key population in the		
	catchment area		
	By key population type:		
	Female sex workers (FSW)		
	(Numerator: Number of key		
	populations reached with		0.07
	individual and/or small group	145	367
	level HIV preventive		
	interventions that are based		
	on evidence and/or meet the		
	minimum standards required)		



By key population type:		
Males who inject drugs (		
Male PWID) (Numerator:		
Number of key populations		
reached with individual		1.076
and/or small group level HIV	0	1,276
preventive interventions that		
are based on evidence		
and/or meet the minimum		
standards required)		
By key population type:		
Females who inject drugs		
(Female PWID) (Numerator:		
Number of key populations		
reached with individual	50	
and/or small group level HIV		25
preventive interventions that		
are based on evidence		
and/or meet the minimum		
standards required)		
By key population type: Men		
who have sex with		
men/Transgender (MSM/TG)		
(Numerator: Number of key		
populations reached with		
individual and/or small group	3,000	4,000
level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
MSM/TG who are male sex		
workers (subset MSM/TG)		
(Numerator: Number of key		
populations reached with		
individual and/or small group		
group		



	1	
level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
Female sex workers (FSW)		
(Denominator: Total		
estimated number of key		
population in the catchment		
area)		
By key population type:		
Males who inject drugs (		
Male PWID) (Denominator:		
Total estimated number of		
key population in the		
catchment area)		
By key population type:		
Females who inject drugs		
(Female PWID)		
(Denominator: Total		
estimated number of key		
population in the catchment		
area)		
By key population type: Men		
who have sex with		
men/Transgender (MSM/TG)		
(Denominator: Total		
stimated number of key		
population in the catchment		
area)		
By key population type:		
MSM/TG who are male sex		
workers (subset MSM/TG)		
(Denominator: Total		
estimated number of key		
population in the catchment		
	1	



	area)		
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	525,557	470,820
	By Test Result: Negative	515,256	460,533
	By Test Result: Positive	10,301	10,287
	Sum of Test Result disaggregates	525,557	470,820
	Test Result by Age and Sex: Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male		
	Test Result by Age and Sex: Positive: 15-19 Male		
	Test Result by Age and Sex: Positive: 20-24 Male		
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		
	Test Result by Age and Sex: Positive: <1 Female		
	Test Result by Age and Sex: Positive: 1-4 Female		
	Test Result by Age and Sex: Positive: 5-9 Female		
	Test Result by Age and Sex: Positive: 10-14 Female		



Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex: Positive: 50+ Female	
Test Result by Age and Sex: Negative: <1 Male	
Test Result by Age and Sex: Negative: 1-4 Male	
Test Result by Age and Sex: Negative: 5-9 Male	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex: Negative: 20-24 Male	
Test Result by Age and Sex: Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex: Negative: <1 Female	
Test Result by Age and Sex: Negative: 1-4 Female	
Test Result by Age and Sex:	
Negative: 5-9 Female	
Test Result by Age and Sex: Negative: 10-14 Female	
Test Result by Age and Sex:	
Negative: 15-19 Female	



Test Result by Age and Sex: Negative: 20-24 Female		
Test Result by Age and Sex:		
Negative: 25-49 Female		
Test Result by Age and Sex: Negative: 50+ Female		
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	890	895
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	113,374	111,090
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	480	475
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	410,813	358,360
Sum of Aggregated Age/Sex <15	1,370	1,370
Sum of Aggregated Age/Sex 15+	524,187	469,450
Sum of Aggregated Age/Sex disaggregates	525,557	470,820
Service Delivery Point by Result: Antenatal Clinic - All results		
Service Delivery Point by Result: Antenatal Clinic - Positive		
Service Delivery Point by Result: Antenatal Clinic - Negative		
Service Delivery Point by Result: Labor & delivery - All		



results	
Service Delivery Point by	
Result: Labor & delivery -	
Positive	
Service Delivery Point by	
Result: Labor & delivery -	
Negative	
Service Delivery Point by	
Result: Under 5 Clinic – All	
results	
Service Delivery Point by	
Result: Under 5 Clinic -	
Positive	
Service Delivery Point by	
Result: Under 5 Clinic -	
Negative	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic – All Results	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Positive	 
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Negative	
Service Delivery Point by	
Result: Tuberculosis – All	
results	
Service Delivery Point by	
Result: Tuberculosis -	
Positive	 
Service Delivery Point by	
Result: Tuberculosis -	
Negative	 
Service Delivery Point by	 



Result: Sexually Transmitted	
Infections – All Results	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Positive	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Negative	
Service Delivery Point by	
Result: Outpatient	
Department – All Results	
Service Delivery Point by	
Result: Outpatient	
Department - Positive	
Service Delivery Point by	
Result: Outpatient	
Department - Negative	
Service Delivery Point by	
Result: Inpatient – All	
Results	
Service Delivery Point by	
Result: Inpatient - Positive	
Service Delivery Point by	
Result: Inpatient - Negative	
Service Delivery Point by	
Result: HIV care and	
treatment clinic – All Results	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Positive	 
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Negative	 
Service Delivery Point by	
Result: Voluntary Medical	



L	
Male Circumcision – All	
Results	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Positive	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) – All	
Results	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) – All	
Results	
Service Delivery Point by Result: Voluntary Counseling	
& Testing (stand alone) – Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) –	
Negative	
Service Delivery Point by	
Result: Mobile – All Results	
Service Delivery Point by	



	Result: Mobile - Positive		
	Service Delivery Point by		
	Result: Mobile - Negative		
	Service Delivery Point by		
	Result: Home-based – All		
	Results		
	Service Delivery Point by		
	Result: Home-based -		
	Positive		
	Service Delivery Point by		
	Result: Home-based -		
	Negative		
	Service Delivery Point by		
	Result: Other – All Results		
	Service Delivery Point by		
	Result: Other - Positive		
	Service Delivery Point by		
	Result: Other - Negative		
	Number of individuals who		
	received T&C services for		
	HIV and received their test	15,000	
	results during the past 12		
	months		
	By Test Result: Negative		
	By Test Result: Positive		
	Sum of Test Result		
HTC_TST_NA	disaggregates		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		



	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Male	10,500	10,500
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: 15+ Female	4,500	4,500
	Sum of Aggregated Age/Sex <pre>&lt;15</pre>		
	Sum of Aggregated Age/Sex	15,000	15,000
	Sum of Aggregated Age/Sex disaggregates	15,000	15,000
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	540,557	
	By Test Result: Negative	529,819	
	By Test Result: Positive	10,738	
	Sum of Test Result disaggregates	540,557	



	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Age/sex: <15 Male	890	
	Aggregated Age/sex: 15+ Male	123,874	
	Aggregated Age/sex: <15 Female	480	
	Aggregated Age/sex: 15+ Female	415,313	
	Sum of Aggregated Age/Sex <pre>&lt;15</pre>	1,370	
	Sum of Aggregated Age/Sex 15+	539,187	
	Sum of Aggregated Age/Sex disaggregates	540,557	
HTC_TST_TA	Number of individuals who	41,000	135,810



received T&C services for		
HIV and received their test		
results during the past 12		
months		
By Test Result: Negative	40,563	133,847
By Test Result: Positive	437	1,963
Sum of Test Result	14.000	
disaggregates	41,000	135,810
Test Result by Age and Sex:		
Positive: <1 Male		
Test Result by Age and Sex:		
Positive: 1-4 Male		
Test Result by Age and Sex:		
Positive: 5-9 Male		
Test Result by Age and Sex:		
Positive: 10-14 Male		
Test Result by Age and Sex:		
Positive: 15-19 Male		
Test Result by Age and Sex:		
Positive: 20-24 Male		
Test Result by Age and Sex:		
Positive: 25-49 Male		
Test Result by Age and Sex:		
Positive: 50+ Male		
Test Result by Age and Sex:		
Positive: <1 Female		
Test Result by Age and Sex:		
Positive: 1-4 Female		
Test Result by Age and Sex:		
Positive: 5-9 Female		
Test Result by Age and Sex:		
Positive: 10-14 Female		
Test Result by Age and Sex:		
Positive: 15-19 Female		



Test Result by Age and Sex: Positive: 20-24 Female		
Test Result by Age and Sex:		
Positive: 25-49 Female		
Test Result by Age and Sex:		
Positive: 50+ Female		
Test Result by Age and Sex:		
Negative: <1 Male		
Test Result by Age and Sex:		
Negative: 1-4 Male		
Test Result by Age and Sex:		
Negative: 5-9 Male		
Test Result by Age and Sex:		
Negative: 10-14 Male		
Test Result by Age and Sex:		
Negative: 15-19 Male		
Test Result by Age and Sex:		
Negative: 20-24 Male		
Test Result by Age and Sex:		
Negative: 25-49 Male		
Test Result by Age and Sex:		
Negative: 50+ Male		
Test Result by Age and Sex:		
Negative: <1 Female		
Test Result by Age and Sex:		
Negative: 1-4 Female		
Test Result by Age and Sex:		
Negative: 5-9 Female		
Test Result by Age and Sex:		
Negative: 10-14 Female		
Test Result by Age and Sex:		
Negative: 15-19 Female		
Test Result by Age and Sex:		
Negative: 20-24 Female		
	1	



Test Result by Age a		
Negative: 25-49 Fem	nale	
Test Result by Age a Negative: 50+ Fema		
Aggregated Age/sex WITH HQ PERMISS ONLY: <15 Male		5
Aggregated Age/sex WITH HQ PERMISS ONLY: 15+ Male		16,760
Aggregated Age/sex WITH HQ PERMISS ONLY: <15 Female		5
Aggregated Age/sex WITH HQ PERMISS ONLY: 15+ Female		119,040
Sum of Aggregated / <15	Age/Sex 0	10
Sum of Aggregated / 15+	Age/Sex 41,000	135,800
Sum of Aggregated disaggregates	Age/Sex 41,000	135,810
Service Delivery Poi Result: Antenatal Cli results		
Service Delivery Poi Result: Antenatal Cli Positive	-	
Service Delivery Poi Result: Antenatal Cli Negative	-	
Service Delivery Poi Result: Labor & deliv results	-	
Service Delivery Poi	nt by	



Re	esult: Labor & delivery -	
Pc	ositive	
Se	ervice Delivery Point by	
Re	esult: Labor & delivery -	
Ne	egative	
Se	ervice Delivery Point by	
Re	esult: Under 5 Clinic – All	
re	sults	
Se	ervice Delivery Point by	
Re	esult: Under 5 Clinic -	
Pc	ositive	
Se	ervice Delivery Point by	
Re	esult: Under 5 Clinic -	
Ne	egative	
Se	ervice Delivery Point by	
Re	esult: Maternal and Child	
He	ealth Clinic – All Results	
Se	ervice Delivery Point by	
Re	esult: Maternal and Child	
He	ealth Clinic - Positive	
Se	ervice Delivery Point by	
Re	esult: Maternal and Child	
He	ealth Clinic - Negative	
Se	ervice Delivery Point by	
Re	esult: Tuberculosis – All	
re	sults	
Se	ervice Delivery Point by	
Re	esult: Tuberculosis -	
Po	ositive	
Se	ervice Delivery Point by	
Re	esult: Tuberculosis -	
Ne	egative	
Se	ervice Delivery Point by	
Re	esult: Sexually Transmitted	
Ini	fections – All Results	



Service Delivery Point by		
Result: Sexually Transmitted		
Infections - Positive		
Service Delivery Point by		
Result: Sexually Transmitted		
Infections - Negative		
Service Delivery Point by		
Result: Outpatient		
Department – All Results		
Service Delivery Point by		
Result: Outpatient		
Department - Positive		
Service Delivery Point by		
Result: Outpatient		
Department - Negative		
Service Delivery Point by		
Result: Inpatient – All		
Results		
Service Delivery Point by		
Result: Inpatient - Positive		
Service Delivery Point by		
Result: Inpatient - Negative		
Service Delivery Point by		
Result: HIV care and		
treatment clinic – All Results		
Service Delivery Point by		
Result: HIV care and		
treatment clinic - Positive		
Service Delivery Point by		
Result: HIV care and		
treatment clinic - Negative		
Service Delivery Point by		
Result: Voluntary Medical		
Male Circumcision – All		
 Results		
	·	·



Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Positive	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) – All	
Results	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) - All	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (standalone) -	
Negative	
Service Delivery Point by	
Result: Mobile – All Results	
Service Delivery Point by	
Result: Mobile - Positive	
Service Delivery Point by	
Result: Mobile - Negative	



		1	
	Service Delivery Point by		
	Result: Home-based – All		
	Results		
	Service Delivery Point by		
	Result: Home-based -		
	Positive		
	Service Delivery Point by		
	Result: Home-based -		
	Negative		
	Service Delivery Point by		
	Result: Other – All Results		
	Service Delivery Point by		
	Result: Other - Positive		
	Service Delivery Point by		
	Result: Other - Negative		
	Number of active		
	beneficiaries served by		
	PEPFAR OVC programs for	2,270	
	children and families affected		
	by HIV/AIDS		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
OVC_SERV_DSD	Age/Sex: 15-17 Male		
	By: Age/sex: Male 18-24		
	By: Age/sex: Male 25+		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By: Age/sex: 18-24 Female		
	By: Age/sex: 25+ Female		



Sum of Age/Sex	
disaggregates	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female <1	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 5-9	
Required only for DREAMS	 
countries - By service, age	
and sex: Education Support	
Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male <1	
Required only for DREAMS	



countries - By service, age		
and sex: Education Support		
Male 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 5-9		
. ~	1	



Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
5 5	



1	 
Programs Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 18-24	
Required only for DREAMS	
countries - By service, age	
nd sex: Parenting/Caregiver	
rograms Male 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female <1	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female 1-4	
Required only for DREAMS	
countries - By service, age	
ind sex: Social Protection	
emale 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female 18-24	
Required only for DREAMS	
countries - By service, age	



and sex: Social Protection Female 25+	
Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
Required only for DREAMS	



1	1	
countries - By service, age		
and sex: Economic		
Strengthening Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male <1		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male 5-9		



	Required only for DREAMS		
	countries - By service, age		
	and sex: Economic		
	Strengthening Male 10-14		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Economic		
	Strengthening Male 15-17		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Economic		
	Strengthening Male 18-24		
	Required only for DREAMS		
	countries - By service, age		
	and sex: Economic		
	Strengthening Male 25+		
	Number of active		
	beneficiaries served by		
	PEPFAR OVC programs for	4,130	
	children and families affected		
	by HIV/AIDS		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
OVC_SERV_TA	Age/Sex: 15-17 Male		
	By age/sex: 18-24 Male		
	By age/sex: 25+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	By age/sex: 18-24 Female		



By age/sex: 25+ Female		
Sum of Age/Sex		
disaggregates		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female <1		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female 1-4		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female 5-9		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
-		
Support Female 10-14		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female 15-17		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female 18-24		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Female 25+		
Required only for DREAMS		
countries: By Service Area,		
age and sex: Education		
Support Male <1		
- · · · · · · · · · · · · · · · · · · ·	1	



Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female <1	
Required only for DREAMS	 
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 1-4	
Required only for DREAMS	
· ·	



countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Parenting/Caregiver Program	
Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 1-4	
Required only for DREAMS	
countries: By Service Area,	



age and sex: Parenting/Caregiver Program	
Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
 Protection Female 5-9	



Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
ago ana oon. ooolai	



Protection Male 15-17	
Required only for DREA	IS
countries: By Service Ar	ea,
age and sex: Social	
Protection Male 18-24	
Required only for DREA	//S
countries: By Service Ar	ea,
age and sex: Social	
Protection Male 25+	
Required only for DREA	<i>I</i> S
countries: By Service Ar	ea,
age and sex: Economic	
Strengthening Female <	
Required only for DREA	лs
countries: By Service Ar	
age and sex: Economic	
Strengthening Female 1	4
Required only for DREA	//S
countries: By Service Ar	
age and sex: Economic	
Strengthening Female 5	9
Required only for DREA	лs
countries: By Service Ar	
age and sex: Economic	
Strengthening Female 1	)-14
Required only for DREA	//S
countries: By Service Ar	
age and sex: Economic	
- Strengthening Female 1	j-17
Required only for DREA	//S
countries: By Service Ar	
age and sex: Economic	
Strengthening Female 1	3-24
Required only for DREA	//S
countries: By Service Ar	



L	
age and sex: Economic	
Strengthening Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 18-24	
Required only for DREAMS	
countries: By Service Area, age and sex: Economic	
Strengthening Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female <1	
Required only for DREAMS	



	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 1-4		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 5-9		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 10-14		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 15-17		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 18-24		
	Required only for DREAMS		
	countries: By Service Area,		
	age and sex: Other Service		
	Areas Female 25+		
	Number of HIV-positive		
	individuals receiving a	67,110	
	minimum of one clinical	07,110	
	service		
	By Age/Sex: <15 Female	1,950	
	By Age/Sex: <15 Male	1,830	
C2.1.D_DSD	By Age/Sex: 15+ Female	22,190	
	By Age/Sex: 15+ Male	41,140	
	Sum of Age/Sex		
	disaggregates	67,110	
	By Age: <15	3,780	
	By Age: 15+	63,330	
	2, , .go. 101	00,000	



	Sum of Age disaggregates	67,110	
	By Sex: Female	24,020	
	By Sex: Male	43,090	
	Sum of Sex disaggregates	67,110	
	Number of HIV-positive individuals receiving a minimum of one clinical service	67,110	
	By Age/Sex: <15 Female	1,950	
	By Age/Sex: <15 Male	41,140	
	By Age/Sex: 15+ Female	1,830	
	By Age/Sex: 15+ Male	22,190	
C2.1.D_NGI	Sum of Age/Sex disaggregates	67,110	
	By Age: <15	3,780	
	By Age: 15+	63,330	
	Sum of Age disaggregates	67,110	
	By Sex: Female	24,020	
	By Sex: Male	43,090	
	Sum of Sex disaggregates	67,110	
	Number of HIV-positive individuals receiving a minimum of one clinical service	6,650	
	By Age/Sex: <15 Female	140	
	By Age/Sex: <15 Male	3,860	
C2.1.D_TA	By Age/Sex: 15+ Female	130	
	By Age/Sex: 15+ Male	2,520	
	Sum of Age/Sex disaggregates	6,650	
	By Age: <15	270	
	By Age: 15+	6,380	
	Sum of Age disaggregates	6,650	



	By Sex: Female	4,000	
	By Sex: Male	2,650	
	Sum of Sex disaggregates	6,650	
	C2.4.D_DSD TB/HIV: Percent of HIV-positive patients who were screened for TB in HIV care or treatment setting	91 %	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	61,340	
	Number of HIV-positive individuals receiving a minimum of one clinical service	67,110	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load Age/sex: <1 Male Age/sex: 1-4 Male Age/sex: 5-9 Male Age/sex: 5-9 Male Age/sex: 15-19 Male Age/sex: 20-24 Male Age/sex: 25-49 Male		71,480
	Age/sex: 50+ Male Age/sex: <1 Female Age/sex: 1-4 Female Age/sex: 5-9 Female		



	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sun of Age/Sex disaggregates	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,110
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,140
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,970
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,260
	Sum of Aggregated Age/Sex disaggregates	71,480
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,800
CARE_CURR_TA	Age/sex: <1 Male	
	Age/sex: 1-4 Male	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	



	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: <1 Female	
	Age/sex: 1-4 Female	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	230
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,050
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	210
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,310
	Sum of Aggregated Age/Sex disaggregates	8,800
	Number of HIV-infected adults and children newly	
	enrolled in clinical care	
CARE_NEW_DSD	during the reporting period and received at least one of	9,170
	the following at enrollment:	
	clinical assessment (WHO	
	staging) OR CD4 count OR	



	viral load		
	Age/sex: <1 Male		
	Age/sex: 1-4 Male		
	Age/sex: 5-9 Male		
	Age/sex: 10-14 Male		
	Age/sex: 15-19 Male		
	Age/sex: 20-24 Male		
	Age/sex: 25-49 Male		
	Age/sex: 50+ Male		
	Age/sex: <1 Female		
	Age/sex: 1-4 Female		
	Age/sex: 5-9 Female		
	Age/sex: 10-14 Female		
	Age/sex: 15-19 Female		
	Age/sex: 20-24 Female		
	Age/sex: 25-49 Female		
	Age/sex: 50+ Female		
	Sum of Age/sex		
	disaggregates		
	Aggregated Age/sex: <15 Male		250
	Aggregated Age/sex: 15+ Male		5,420
	Aggregated Age/sex: <15 Female		240
	Aggregated Age/sex: 15+ Female		3,260
	Sum of Aggregated Age/sex disaggregates		9,170
	CARE_SITE Percentage of		
	PEPFAR-supported HIV	n/a	
CARE_SITE	clinical care sites at which at	ıı/d	
	least 80% of PLHIV received		



all of the following during the	
reporting period: 1) clinical	
assessment (WHO staging)	
OR CD4 count OR viral load,	
AND 2) TB screening at last	
visit, AND 3) if eligible,	
cotrimoxazole	
Number of	-
PEPFAR-supported HIV	
clinical care sites at which at	
least 80% of PLHIV received	
all of the following during	
the reporting period: 1)	181
clinical assessment (WHO	
staging) OR CD4 count OR	
viral load, AND 2) TB	
screening at last visit, AND	
3) if eligible, cotrimoxazole	
Total number of PEPFAR	
supported sites providing	197
clinical care services	
By site support type: Direct	
Service Delivery (DSD):	
Number of	
PEPFAR-supported HIV	
clinical care sites at which at	
least 80% of PLHIV received	
all of the following during the	98
reporting period: 1) clinical	50
assessment (WHO staging)	
OR CD4 count OR viral load,	
AND 2) TB screening at last	
visit, AND 3) if eligible,	
cotrimoxazole	
By site support type:	83
Technical Assistance-only	



	(TA): Number of		
	PEPFAR-supported HIV		
	clinical care sites at which at		
	least 80% of PLHIV received		
	all of the following during		
	the reporting period: 1)		
	clinical assessment (WHO		
	staging) OR CD4 count OR		
	viral load, AND 2) TB		
	screening at last visit, AND		
	3) if eligible, cotrimoxazole		
	Sum of Numerator Site		
	Support Type disaggregates		181
	By site support type: Direct		
	Service Delivery (DSD):		
	Total number of PEPFAR		102
	supported sites providing		102
	clinical care services		
	By site support type: Technical Assistance-only		
	(TA): Total number of		
	PEPFAR supported sites		95
	PEPPAR supported sites		
	providing alipical core		
	providing clinical care		
	services		
	Sum of Denominator Site		197
	Sum of Denominator Site Support Type disaggregates		197
	Sum of Denominator Site Support Type disaggregates FN_THER_DSD Proportion		197
	Services Sum of Denominator Site Support Type disaggregates FN_THER_DSD Proportion of clinically undernourished		197
	Services Sum of Denominator Site Support Type disaggregates FN_THER_DSD Proportion of clinically undernourished PLHIV who received	100 %	197
	Services Sum of Denominator Site Support Type disaggregates FN_THER_DSD Proportion of clinically undernourished	100 %	197
EN THER DSD	Services Sum of Denominator Site Support Type disaggregates FN_THER_DSD Proportion of clinically undernourished PLHIV who received	100 %	197
FN_THER_DSD	services         Sum of Denominator Site         Support Type disaggregates         FN_THER_DSD Proportion         of clinically undernourished         PLHIV who received         therapeutic or supplementary	100 %	197
FN_THER_DSD	services         Sum of Denominator Site         Support Type disaggregates         FN_THER_DSD Proportion         of clinically undernourished         PLHIV who received         therapeutic or supplementary         food	100 %	197
FN_THER_DSD	services         Sum of Denominator Site         Support Type disaggregates         FN_THER_DSD Proportion         of clinically undernourished         PLHIV who received         therapeutic or supplementary         food         Number of clinically	100 %	197
FN_THER_DSD	services         Sum of Denominator Site         Support Type disaggregates         FN_THER_DSD Proportion         of clinically undernourished         PLHIV who received         therapeutic or supplementary         food         Number of clinically         malnourished PLHIV who		



Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,200	1,200
Age: <1		
Age: 1-4		
Age: 5-14		
Age: 15-17		
Age: 18+		
Sum of Age disaggregates		
Aggregated Age: <18	217	217
Aggregated Age: 18+	983	983
Sum of Aggregated Age disaggregates	1,200	1,200
By Pregnancy/Postpartum Status: Pregnant		
By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
The number of registered new and relapse TB cases with documented HIV-positive status whoare		1,756
during the reporting period		
The number of registered new and relapse TB cases		
with documented HIV-positive status during TB treatment during the		2,195
	nutritionally assessed and found to be clinically undernourished.Age: <1	nutritionally assessed and found to be clinically undernourished.1,200Age: <1



	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		
	Female		
	Sum of Sex disaggregates		
	Newly tested		
	Known HIV-positive		
	Sum of Test Status		
	disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age		
	disaggregates		
	Timeliness: Art initiation <8		
	weeks of start of TB		
	treatment		
	Timeliness: Art initiation >8		
	weeks of start of TB		
	TB_ARTSITE Proportion of		
	PEPFAR-supported TB basic management units at which		
	80% of registered TB cases	n/a	
	who are HIV-positive are on		
TB_ARTSITE	ART		
	The number of		
	PEPFAR-supported TB basic		47
	management units at which		47
	80% of registered TB cases		



who are HIV-positive are on	
ART, during the reporting	
period	
The number of	
PEPFAR-supported TB basic	65
management units	
By site support type: Direct	
Service Delivery (DSD): The	
number of	
PEPFAR-supported TB basic	
management units at which	47
80% of registered TB cases	
who are HIV-positive are on	
ART, during the reporting	
period	
By site support type:	
Technical Assistance-only	
(TA): The number of	
PEPFAR-supported TB basic	
nanagement units at which	
0% of registered TB cases	
who are HIV-positive are on	
ART, during the reporting	
period	
Sum of Numerator Site	
Support Type disaggregates	47
By site support type: Direct	
Service Delivery (DSD): The	
number of	65
PEPFAR-supported TB basic	
management units	
By site support type:	
echnical Assistance-only	
TA): The number of	
EPFAR-supported TB basic	
management units	



	Sum of Denominator Site		65
	Support Type disaggregates		
	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical	n/a	
	visit to an HIV care facility during the reporting period.		
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		66,000
	Number of HIV positive adults and children who received at least one of the following during the reporting		71,480
TB_SCREEN_DSD	period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4 Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		



	Sex: Male		
	Sex: Female		
	Sum of Sex disaggregates		
	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	98 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,350	1,360
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,375	1,365
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,070	1,080
	By infants who received their first virologic HIV test between 2 and 12 months of age	280	280
	Sum of Infant Age disaggregates	1,350	1,360
	By infants with a positive virologic test result within 12 months of birth	92	90
	Number of infants with a positive virological test result within 2 months of birth		
	Number of infants with a positive virological test result		



	within 12 months of birth		
	Number of adults and children receiving antiretroviral therapy (ART)	46,800	49,200
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Aggregated Age/Sex: <1 Male	43	13
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	42	13
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	28,570	29,930
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	14,685	15,350
	Sum of Aggregated Age/Sex <15	3,545	3,920
	Sum of Aggregated Age/Sex 15+	43,255	45,280
	Sum of Aggregated Age/Sex disaggregates	46,800	49,200
TX_CURR_NGI	Number of adults and	46,800	



	children receiving		
	antiretroviral therapy (ART)		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15+ Female		
	Sum of Age/Sex disaggregates		
	Aggregated Age/Sex: <1 Male	43	
	Aggregated Age/Sex: <1 Female	42	
	Aggregated Age/Sex: <15 Male	1,850	
	Aggregated Age/Sex: 15+ Male	28,570	
	Aggregated Age/Sex: <15 Female	1,695	
	Aggregated Age/Sex: 15+ Female	14,685	
	Sum of Aggregated Age/Sex disaggregates	46,800	
	Sum of Aggregated Age/Sex <15	3,545	
	Sum of Aggregated Age/Sex 15+	43,255	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,800	6,600
	Age/Sex: <1 Male		



	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Sum of Age/Sex disaggregations		
	Aggregated Age/Sex: <1 Male	5	5
	Aggregated Age/Sex: <1 Female	5	5
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	3,670	4,200
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	1,950	2,220
	Sum of Aggregated Age/Sex <15	180	180
	Sum of Aggregated Age/Sex 15+	5,620	6,420
	Sum of Aggregated Age/Sex disaggregates	5,800	6,600
TX_DIST	TX_DIST Percentage of Districts that are PEPFAR supported with documented routine supportive supervision visits to 75% of	n/a	



	ART sites in District		
	Number of Districts with		
	documented routine		
	supportive supervision visits		
	to 75% of HIV care and		
	treatment sites supported by		
	the District		
	Total number of PEPFAR		
	supported District Health		
	Offices		
	Number of adults and		
	children newly enrolled on	7,200	7,000
	antiretroviral therapy (ART)		
	By Age/Sex: <1 Male		
	By Age/Sex: 1-4 Male		
	By Age/Sex: 5-9 Male		
	By Age/Sex: 10-14 Male		
	By Age/Sex: 15-19 Male		
	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
TX_NEW_DSD	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
	By Age/Sex: 50+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Grouping by		
	Age: <1 Male	35	10



	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	4,470	4,347
	Aggregated Grouping by Age/Sex: <1 Female	35	10
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female	2,320	2,257
	Sum of Aggregated Age/Sex disaggregates Pregnancy status	7,200	7,000
	Breastfeeding status		
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	89 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,157	7,454
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,016	8,328
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at		



12 months after initiating ART)	
Age/Sex: 5-14 Male (Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating	
ART)	 
Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
Age/Sex: <5 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	 
Age/Sex: 5-14 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 15-19 Female (Numerator: Number of	
adults and children who are	
still alive and on treatment at	



	L.	
12 months after initiating		
ART)		
Age/Sex: 20+ Female		
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		
12 months after initiating		
ART)		
Age/Sex: <5 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 5-14 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 15-19 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		



stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: <5 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 5-14 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	



	months prior to the beginning		
	of the reporting period,		
	including those who have		
	died, those who have		
	stopped ART, and those lost		
	to follow-up)		
	Age/Sex: 20+ Female		
	(Denominator: Total number		
	of adults and children who		
	initiated ART in the 12		
	months prior to the beginning		
	of the reporting period,		
	including those who have		
	died, those who have		
	stopped ART, and those lost		
	to follow-up)		
	Numerator by Status:		
	Pregnant		
	Numerator by Status:		
	Breastfeeding		
	Denominator by Status:		
	Pregnant		
	Denominator by Status:		
	Breastfeeding		
	TX_SITE Percentage of		
	_ 3		
	PEPFAR-supported ART	n/a	
	sites achieving a 75% ART		
	retention rate		
	Number of		
TX_SITE	PEPFAR-supported ART		
	sites with a retention rate of		121
	75% or greater for patients		
	12 months after ART		
	initiation		
	Total number of		127



PEPFAR-supported ART		
sites		
By support type: Direct		
Number of		
PEPFAR-supported ART		
sites with a retention rate of		97
75% or greater for patients		
12 months after ART		
initiation		
By support type: Technical		
Number of		
PEPFAR-supported ART		
sites with a retention rate of		24
75% or greater for patients		
12 months after ART		
initiation		
Sum of Numerator Site		101
Support Type disaggregates		121
By support type: Direct		
Total number of		102
PEPFAR-supported ART		
sites		
By support type: Technical		
number of		27
PEPFAR-supported ART		
sites		
Sum of Denominator Site		
		129
	83	103
are recognized by national,		
	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Sum of Numerator Site Support Type disaggregates By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites Sum of Denominator Site Sum of Denominator Site Support Type disaggregates Number of PEPFAR-supported testing facilities (laboratories) that	By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation Sum of Numerator Site Support Type disaggregates By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites Sum of Denominator Site Support Type disaggregates Number of PEPFAR-supported testing facilities (laboratories) that



	regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation Number of PEPFAR-supported testing facilities with capacity to	1,288	1,627
LAB_CAP_DSD	perform clinical laboratory tests		
	By clinical laboratories	1	
	By Point-of-care testing sites		
	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	25	25
	By Graduates: Doctors		
HRH_PRE	By Graduates: Nurses		
	By Graduates: Midwives By Graduates: Social service workers		
	By Graduates: Laboratory professionals		
	By Graduates: Other	25	25
	Sum of Graduates disaggreagtes	25	25
SC_TRAIN	SC_TRAIN Percentage of individuals who received competency-based, certificate, or higher-level	n/a	



training to conduct or support	
supply chain, inventory	
management, supportive	
supervision or distribution	
activities	
Number of individuals who	
received competency-based,	
certificate or higher-level	
training to conduct or support	10
supply chain, inventory	10
management, supportive	
supervision or distribution	
activities	
Number of individuals who	
conduct or support supply	
chain, inventory	
management, supportive	15
supervision or distribution	
activities	
By: Individuals trained in a	
nationally- or	
internationally-recognized	
pre-service training program	
By: Individuals who passed a	
competency-based training	
to conduct supply chain	
activities	
By: Individuals who passed a	
competency-based training	
to perform inventory	
management	
By: Individuals who passed a	
competency-based training	
to develop distribution plans	
By: Individuals who passed a	
competency-based training	



	to perform supportive		
	supervision		
	By: Individuals who passed a		
	competency-based training		
	to perform quantification		
	QI_SITE Percentage of		
	PEPFAR-supported clinical		
	service sites with quality		
	improvement activities		
	implemented that address	n/a	
	clinical HIV program		
	processes or outcomes and		
	have documented process		
	results in the last 6 months		
	Number of		
	PEPFAR-supported clinical		
	service sites with a quality		
	improvement activity		130
	completed that addresses		130
	clinical HIV programs and		
QI_SITE	has documented process		
	results in the last 6 months		
	Total number of		
	PEPFAR-supported sites for		
	any HIV clinical service		
	including HIV Care, HIV		309
	Treatment, TB care, PMTCT,		
	VMMC, and HTC		
	By site support type: Direct		
	Service Delivery (DSD):		
	Number of		
	PEPFAR-supported clinical		
	service sites with a quality		88
	improvement activity		
	completed that addresses		
	clinical HIV programs and		



has documented results in	
the last 6 months	
By site support type:	
Technical Assistance-only	
(TA): Number of	
PEPFAR-supported clinical	
service sites with a quality	42
improvement activity	42
completed that addresses	
clinical HIV programs and	
has documented results in	
the last 6 months	
Sum of Numerator Site	120
Support Type disaggregates	130
By site support type: Direct	
Service Delivery (DSD):	
Total number of	
PEPFAR-supported sites for	007
any HIV clinical service	267
including HIV Care, HIV	
Treatment, TB care, PMTCT,	
VMMC, HTC	
By site support type:	
Technical Assistance-only	
(TA): Total number of	
PEPFAR-supported sites for	10
any HIV clinical service	42
including HIV Care, HIV	
Treatment, TB care, PMTCT,	
VMMC, and HTC	 
Sum of Denominator Site	
Support Type disaggregates	309



# Partners and Implementing Mechanisms

#### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7345	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	12,000,000
7348	United Nations Joint Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
9972	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	210,000
9973	Hanoi School of Public Health	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	278,500
9974	Ho Chi Minh City Provincial AIDS Committee	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,738,000
9976	Ministry of Health,	Host Country	U.S. Department	GHP-State, GAP	8,466,529



	Vietnam	Government	of Health and		
		Agency	Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	National Institute	Host Country	Human		
9977	for Hygiene and	Government	Services/Centers	GHP-State	350,000
	Epidemiology	Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
		Host Country	Human		
9998	Pasteur Institute	Government	Services/Centers	GHP-State	400,000
		Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Ministry of Labor,	Host Country	Human		
9999	Invalids and	Government	Services/Centers	GHP-State	0
	Social Affairs	Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Harvard Medical		Human		
10000	School of AIDS	University	Services/Centers	GHP-State	1,353,000
	Initiative in		for Disease		
	Vietnam		Control and		
			Prevention		
10001	TBD	TBD	Redacted	Redacted	Redacted
10118	Vietnam	Implementing	U.S. Department	GHP-State	290,000



Administration for	Agency	of Health and		
Medical Sciences		Human		
		Services/Centers		
		for Disease		
		Control and		
		Prevention		
		U.S. Department		
		of Health and		
		Human		
-	NGO	Services/Centers	GHP-State	240,000
		for Disease		
Institute		Control and		
		Prevention		
		U.S. Department		
		of Health and		
American Society		Human		
of Clinical	NGO	Services/Centers	GHP-State	210,000
Pathology		for Disease		
		Control and		
		Prevention		
U.S. Department				
of Health and		-		
Human				
	Implementing			
			GHP-State	0
	3			
		Control and		
		Prevention		
		U.S. Department		
U.S. Department	Other USG			
			GHP-State	0
Vietnam Nurses'	Implementing			
Association		-	GHP-State	0
Innovative New	NGO	of Health and	GHP-State	315,000
	Medical SciencesClinical and Laboratory Standards InstituteAmerican Society of Clinical PathologyU.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)U.S. Department of StateVietnam Nurses' AssociationFoundation for	Clinical and Laboratory Standards InstituteNGOAmerican Society of Clinical PathologyNGOU.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)Implementing AgencyU.S. Department of Jisease for Disease Control and Prevention (HHS/CDC)Other USG AgencyU.S. Department of StateOther USG AgencyVietnam Nurses' AssociationImplementing AgencyVietnam Nurses' AgencyImplementing AgencyFoundation for NGONGO	Medical SciencesJunch StateMedical SciencesServices/Centers for Disease Control and PreventionClinical and LaboratoryNGOStandards InstituteNGOStandards InstituteNGOAmerican Society of Clinical PathologyNGOU.S. Department of Health and Human Services/Centers for Disease Control and PreventionU.S. Department of Clinical PathologyNGOU.S. Department of Health and Human Services/Centers for Disease Control and PreventionU.S. Department of StateU.S. Department of StateU.S. Department of StateU.S. Department of StateU.S. Department of StateVietnam Nurses' AgencyVietnam Nurses' AgencyVietnam Nurses' AgencyImplementing AgencyVietnam Nurses' Foundation forNGOU.S. Department of DefenseVietnam Nurses' Foundation forNGOU.S. Department of Defense	Medical SciencesHuman Services/Centers for Disease Control and PreventionClinical and Laboratory Standards InstituteNGOU.S. Department of Health and Human Services/Centers for Disease Control and PreventionGHP-StateAmerican Society of Clinical PathologyNGOU.S. Department of Health and Human Services/Centers for Disease Control and PreventionGHP-StateU.S. Department of Clinical PathologyNGOU.S. Department of Health and Human Services/Centers for Disease Control and PreventionGHP-StateU.S. Department of Health and Human Services/Centers for Disease Control and PreventionGHP-StateU.S. Department of Health and Human Services/Centers for Disease Control and PreventionGHP-StateU.S. Department of Jesase Control and PreventionGHP-StateU.S. Department of StateOther USG AgencyU.S. Department of State/Bureau of AgencyGHP-StateU.S. Department of StateOther USG AgencyU.S. Department of State/Bureau of AgencyGHP-StateVietnam Nurses' AssociationImplementing AgencyU.S. Department of DefenseGHP-StateVietnam Nurses' Foundation for NGOU.S. Department of DefenseGHP-State



	Diagnostics		Human		
	5		Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Agency for		
12750	FHI 360	NGO	International	GHP-State	0
			Development		
	U.S.	Implementing	U.S. Agency for		
12909			International	GHP-State	80,000
	Pharmacopeia	Agency	Development		
			U.S. Department		
			of Health and		
	Vietnam National	Implementing	Human		
13007			Services/Centers	GHP-State	380,000
	TB Program	Agency	for Disease		
			Control and		
			Prevention		
	World Health	Multi-lateral	U.S. Agency for		
13073	Organization	Agency	International	GHP-State	0
	Organization	Agency	Development		
			U.S. Department		
			of Health and		
	University of		Human		
13131	Washington	University	Services/Health	GHP-State	200,000
	Wallington		Resources and		
			Services		
			Administration		
			U.S. Department		
			of Health and		
13147	New York AIDS	Other USG	Human		
	Institute	Agency	Services/Health	GHP-State	14,000
		55	Resources and		
			Services		
			Administration		
13234	KNCV	NGO	U.S. Agency for	GHP-State	1,000,000



	Tuberculosis		International		
	Foundation		Development		
13759	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	0
13779	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human	GHP-State	90,000
13942	University of California at Los Angeles	University	U.S. Department of Health and Human Services/Substan ce Abuse and Mental Health Services Administration	GHP-State	350,000
14048	Hennepin Faculty Associates-Addicti on Medicine Program	Private Contractor	U.S. Department of Health and Human Services/Substan ce Abuse and Mental Health Services Administration	GHP-State	150,000
14086	Management Systems International	Private Contractor	U.S. Agency for International Development	GHP-State	32,000
14156	TBD	TBD	Redacted	Redacted	Redacted
14159	FHI 360	NGO	U.S. Agency for International Development	GHP-State	7,000,000



r					
14326	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
14336	Hanoi Medical University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	701,035
16739	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
16778	TBD	TBD	Redacted	Redacted	Redacted
16803	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	2,000,000
16817	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
16916	TBD	TBD	Redacted	Redacted	Redacted
17369	Armed Forces Research Institute of Medical Sciences	Host Country Government Agency	U.S. Department of Defense	GHP-State	0
17370	Center for Community Health Promotion	NGO	U.S. Department of Defense	GHP-State	0
17371	Abt Associates	Private Contractor	U.S. Agency for International	GHP-State	1,250,000



			Development		
17373	TBD	твр	Redacted	Redacted	Redacted
17374	Center for Community Health and Development	NGO	U.S. Agency for International Development	GHP-State	800,000
17375	The Center for Community Health Research and Development	NGO	U.S. Agency for International Development	GHP-State	700,000
17376	Center for Promotion of Quality of Life	NGO	U.S. Agency for International Development	GHP-State	500,000
17377	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	250,000



# Implementing Mechanism(s)

### **Implementing Mechanism Details**

Mechanism ID: 17377	Mechanism Name: Governance for Inclusive Growth (GIG)		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: Chemonics International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: Yes		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		
Total All Funding Sources: 250,000	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	250,000		

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

# Key Issues

(No data provided.)

# **Budget Code Information**

Mechanism ID: 17377



	Governance for Inclusive Growth (GIG) Chemonics International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

#### Implementing Mechanism Indicator Information

(No data provided.)

### **Implementing Mechanism Details**

Mechanism ID: 17376	Mechanism Name: CSO Life	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Center for Promotion of Quality	y of Life	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	
Total All Funding Sources: 500,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	500,000	

### Sub Partner Name(s)

(No data provided.)

# **Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	56,250
Focus Area:	Training of health workers and community outreach
	workers



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	56,250
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers

(No data provided.)

Mechanism ID: 17376					
Mechanism Name: CSO Life					
Prime Partner Name:	Prime Partner Name: Center for Promotion of Quality of Life				
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Care	HBHC	225,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	OHSS	50,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	HVOP	112,500	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Prevention	IDUP	78,750	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		



Treatment HTXS 33,750 C
-------------------------

#### Implementing Mechanism Indicator Information

(No data provided.)

# **Implementing Mechanism Details**

Mechanism ID: 17375	Mechanism Name: CSO CCRD	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: The Center for Comm	unity Health Research and Development	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 700,000	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	700,000		

#### Sub Partner Name(s)

(No data provided.)

# **Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	60,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	140,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Collection and use of strategic information on SWs
	and clients
Focus Area:	Monitoring and evaluation of SW programs
Condom programming	210,000

(No data provided.)

Mechanism ID:	17375		
Mechanism Name:	CSO CCRD		
Prime Partner Name:	The Center for Community Health Research and Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	207,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	206,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	144,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	62,100	0



# Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 17374	Mechanism Name: CSO COHED	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Center for Community Health and Development		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	
Total All Funding Sources: 800,000         Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	800,000	

# Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	120,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	120,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on



	sexual prevention
Focus Area:	Training of health workers and community outreach
	workers

(No data provided.)

# **Budget Code Information**

Mechanism ID: 17374 Mechanism Name: CSO COHED			
Prime Partner Name:	Center for Community H	lealth and Development	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	168,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	72,000	0

# Implementing Mechanism Indicator Information

(No data provided.)

Custom 2015-03-30 12:28 EDT



### **Implementing Mechanism Details**

Mechanism ID: 17373	TBD: Yes
REDACTED	

#### Implementing Mechanism Details

Mechanism ID: 17371	Mechanism Name: Health Finance & Governance (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: No	
G2G: No Managing Agency:	
Total All Funding Sources: 1,250,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 250,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Eunding Amount

Funding Source	Funding Amount
GHP-State	1,250,000

#### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Key Issues**

(No data provided.)



# **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	Health Finance & Governance (HFG)			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	OHSS	1,250,000	0	

# Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 17370	Mechanism Name: CHP	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: Center for Community Health Promotion		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 1,230,000		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

### Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

Custom 2015-03-30 12:28 EDT



Military Population TB

Mechanism ID:	17370		
Mechanism Name:	СНР		
Prime Partner Name:	Center for Community I	Health Promotion	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	МТСТ	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



	Treatment	HTXS	0	0
--	-----------	------	---	---

# Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	8	8
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	4	2
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	4	2
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	2	2
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	2	2
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0	0
PMTCT_STAT_DSD	Number of new ANC and L&D clients	0	0
PMTCT_STAT_DSD	By: Number of new positives identified	0	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0	0
PMTCT_STAT_NGI	By: Number of new positives identified	0	0
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	0	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,000	20,000
HTC_TST_DSD	By Test Result: Negative	17,830	19,810
HTC_TST_DSD	By Test Result: Positive	170	190
HTC_TST_DSD	Sum of Test Result disaggregates	18,000	20,000
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,580	12,980
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	6,420	7,020



	PERMISSION ONLY: 15+ Female		
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	18,000	20,000
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,000	20,000
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	18,000	20,000
HTC_TST_NGI	By Test Result: Negative	17,830	19,810
HTC_TST_NGI	By Test Result: Positive	170	190
HTC_TST_NGI	Sum of Test Result disaggregates	18,000	20,000
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	11,580	12,980
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	6,420	7,020
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	18,000	20,000
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	18,000	20,000
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	400	
C2.1.D_DSD	By Age/Sex: 15+ Female	100	
C2.1.D_DSD	By Age/Sex: 15+ Male	300	
C2.1.D_DSD	Sum of Age/Sex disaggregates	400	
C2.1.D_DSD	By Age: 15+	400	
C2.1.D_DSD	Sum of Age disaggregates	400	
C2.1.D_DSD	By Sex: Female	100	
C2.1.D_DSD	By Sex: Male	300	
C2.1.D_DSD	Sum of Sex disaggregates	400	
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	400	
C2.1.D_NGI	By Age/Sex: 15+ Female	100	
C2.1.D_NGI	By Age/Sex: 15+ Male	300	
C2.1.D_NGI	Sum of Age/Sex disaggregates	400	
C2.1.D_NGI	By Age: 15+	400	
C2.1.D_NGI	Sum of Age disaggregates	400	
C2.1.D_NGI	By Sex: Female	100	
C2.1.D_NGI	By Sex: Male	300	



		400	
C2.1.D_NGI	Sum of Sex disaggregates	400	
C2.1.D_TA	Number of HIV-positive individuals receiving a	113	
	minimum of one clinical service	10	
C2.1.D_TA	By Age/Sex: 15+ Female	43	
C2.1.D_TA	By Age/Sex: 15+ Male	70	
C2.1.D_TA	Sum of Age/Sex disaggregates	113	
C2.1.D_TA	By Age: 15+	113	
C2.1.D_TA	Sum of Age disaggregates	113	
C2.1.D_TA	By Sex: Female	43	
C2.1.D_TA	By Sex: Male	70	
C2.1.D_TA	Sum of Sex disaggregates	113	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	400	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	400	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	320	320
TX_CURR_DSD	Age/Sex: 15+ Male	240	240
TX_CURR_DSD	Age/Sex: 15+ Female	80	80
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	240	240
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	80	80
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	320	320
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	320	320
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	320	320
TX_CURR_NGI	Age/Sex: 15+ Male	240	240
TX_CURR_NGI	Age/Sex: 15+ Female	80	80
TX_CURR_NGI	Sum of Age/Sex disaggregates	320	320
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	240	240
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	80	80
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	320	320
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	320	320

Approved



TX_CURR_TA	Number of adults and children receiving	113	113
	antiretroviral therapy (ART)		
TX_CURR_TA	Age/Sex: 15+ Male	70	70
TX_CURR_TA	Age/Sex: 15+ Female	43	43
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	70	70
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	43	43
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	113	113
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	113	113
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	50	45
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	35	30
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	15	15
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	50	45
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	45	41
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	50	45
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45	41
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50	45
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45	41



TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50	45
------------	---	----	----

#### **Implementing Mechanism Details**

Mechanism ID: 17369	Mechanism Name: AFRIMS	
Funding Agency: DOD	Procurement Type: Grant	
Prime Partner Name: Armed Forces Research Institute of Medical Sciences		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 520,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

#### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Key Issues**

Military Population



# **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:		n Institute of Medical Scie	ences
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

# Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015
SITE_SUPP	Number of unique sites supported by PEPFAR	8	8
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	8	8
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	2
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2	2
LAB_ACC_DSD	Sum of Support Type disaggregates	2	2
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	5	5
LAB_CAP_DSD	By clinical laboratories	5	5
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	5	5
LAB_CAP_DSD	Sum of Site Support Type disaggregates	5	5



### **Implementing Mechanism Details**

Mechanism ID: 16916	TBD: Yes
REDACTED	

Implementing Mechanism Details			
Mechanism ID: 16817	Mechanism Name: Leadership, Management and Governance – Transition Support Project		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Management Sciences for	Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	0		

### Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

# **Key Issues**

(No data provided.)



# Budget Code Information

	16817 Leadership, Management and Governance – Transition Support Project Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

# Implementing Mechanism Indicator Information

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 16803	Mechanism Name: Healthy Markets	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Program for Appropriate Technology in Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,000,000	000,000 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 1,500,000			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	2,000,000		

### Sub Partner Name(s)

(No data provided.)

2015-03-30 12:28 EDT

Cross-Cutting Budget Attribution(s)		
Human Resources for Health	150,000	
Custom	Page 104 of 194	FACTS Info v3.8.15.8



Key Populations: MSM and TG	250,000
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Implementation of core HIV prevention interventions
	for MSM/TG that are consistent with the current
	PEPFAR technical guidance
Key Populations: FSW	750,000
Focus Area:	Implementation of core HIV prevention interventions
	for SWs consistent with PEPFAR guidance on
	sexual prevention
Focus Area:	Training of health workers and community outreach
	workers
Condom programming	850,000

(No data provided.)

Mechanism Name:	nanism ID: 16803 sm Name: Healthy Markets ner Name: Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0

Approved



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	245,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	105,000	0

# Implementing Mechanism Indicator Information

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 16778	TBD: Yes
REDACTED	

# Implementing Mechanism Details

Mechanism ID: 16739	Mechanism Name: Maternal and Child Health Integrated Program (MCHIP)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
	<u> </u>	

Approved



GHP-State

0

### Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Key Issues**

Safe Motherhood

### **Budget Code Information**

Mechanism ID:	16739		
Mechanism Name:	Maternal and Child Health Integrated Program (MCHIP)		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	PDCS	0	0

# Implementing Mechanism Indicator Information

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 14336	Mechanism Name: HMU		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Hanoi Medical University			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		



Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
Total All Funding Sources: 701,035	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 78,965				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	701,035			

## Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

Human Resources for Health	400,000	
Key Populations: MSM and TG	84,000	
Focus Area:	Collection and use of strategic information	
Focus Area:	Conducting epidemiologic, social science, and	
	operational research among MSM/TG and their sex	
	partners	

# Key Issues

(No data provided.)

Mechanism ID:	14336			
Mechanism Name:	HMU			
Prime Partner Name:	: Hanoi Medical University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and	HLAB	175,500	0	



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	378,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	84,535	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	44,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	18,900	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	4	4	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	4	4	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	4	4	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0	0	Redacted



LAB_ACC_DSD Sum of Support Type disaggregates	4	4	Redacted
---	---	---	----------

#### **Implementing Mechanism Details**

Mechanism ID: 14326	Mechanism Name: UCSF			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: University of California at San	Francisco			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
	Tatal Mashaniam Dinalina, Dadaatad			
Total All Funding Sources: 200,000       Total Mechanism Pipeline: Redacted         Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	200,000			

# Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Key Issues**

(No data provided.)

## **Budget Code Information**

Mechanism ID:	14326		
Mechanism Name:	UCSF		
Prime Partner Name:	University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	200,000	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 14159	Mechanism Name: SMART TA	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

otal All Funding Sources: 7,000,000 Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 2,000,000				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	7,000,000			

# Sub Partner Name(s)

An Giang Provincial AIDS	Can The Dravingial AIDS Contar	Dien Bien Provincial AIDS Center	
Committee	Can Tho Provincial AIDS Center		
Ha Noi Provincial AIDS Committee	Hai Phong Provincial AIDS Center	HCMC Provincial AIDS Committee	
Lao Cai Provincial AIDS Center	National Institute of Nutrition	Nghe An Provincial AIDS Center	
Quang Ninh Provincial AIDS	Thai Binh Provincial AIDS	Vietnem National TP Drogram	
Center	Standing Bureau	Vietnam National TB Program	

# Cross-Cutting Budget Attribution(s)

Custom 2015-03-30 12:28 EDT



Human Resources for Health	1,200,000
Key Populations: MSM and TG	600,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	800,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Food and Nutrition: Commodities	20,000

# Key Issues

(No data provided.)

# **Budget Code Information**

Mechanism ID: Mechanism Name:			
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	276,694	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	336,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,075	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,177,833	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	670,026	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	1,137,753	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,201,044	0

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	35	35
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	0	
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	41	41
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	15	15
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	0	0



c			
SITE_SUPP	By program area/support type: PMTCT Technical Assistance-only (TA)	0	10
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	60	48
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	101	121
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	108	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	120	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	50	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	15	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	35	
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	8	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	40	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	10	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	108	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	50	
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	9	9
PMTCT_SITE	Total number of PEPFAR supported sites	11	11



	providing PMTCT services (HTC and ARV or		
	ART services)		
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	9	9
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women		11
PMTCT_SITE	Sum of Numerator Support Type disaggregates	20	20
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)		9
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	11	11
PMTCT_SITE	Sum of Denominator Support Type disaggregates	20	20
PMTCT_STAT_DSD	By: Known positives at entry	120	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	120	0
PMTCT_STAT_NGI	By: Known positives at entry	120	
PMTCT_STAT_NGI	Sum of Positives Status disaggregates	120	
KP_MAT_DSD	Sex: Male	4,425	2,261
KP_MAT_DSD	Sex: Female	155	79
KP_MAT_DSD	Sum of Sex disaggregates	4,580	2,340
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	45,100	40,590



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	15,500	13,950
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	17,000	15,590
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	700	340
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,900	10,710
HTC_TST_DSD	By Test Result: Negative	46,621	56,823
HTC_TST_DSD	By Test Result: Positive	2,976	3,627
HTC_TST_DSD	Sum of Test Result disaggregates	49,597	60,450
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 27,314		30,840
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,283	29,610
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,597	60,450
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	49,597	60,450
HTC_TST_NGI	By Test Result: Negative	46,621	81,479



HTC_TST_NGI	By Test Result: Positive	2,976	3,971
HTC_TST_NGI	Sum of Test Result disaggregates	49,597	85,450
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	27,314	50,840
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	22,283	34,610
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	49,597	85,450
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	49,597	85,450
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	21,110	
C2.1.D_DSD	By Age/Sex: <15 Female	302	
C2.1.D_DSD	By Age/Sex: <15 Male	274	
C2.1.D_DSD	By Age/Sex: 15+ Female	7,020	
C2.1.D_DSD	By Age/Sex: 15+ Male	13,447	
C2.1.D_DSD	Sum of Age/Sex disaggregates	21,043	
C2.1.D_DSD	By Age: <15	652	
C2.1.D_DSD	By Age: 15+	By Age: 15+ 20,458	
C2.1.D_DSD	Sum of Age disaggregates	21,110	
C2.1.D_DSD	By Sex: Female	7,389	
C2.1.D_DSD	By Sex: Male	13,721	
C2.1.D_DSD	Sum of Sex disaggregates	21,110	
C2.1.D_NGI	Number of HIV-positive individuals receiving a		
C2.1.D_NGI	By Age/Sex: <15 Female	229	
C2.1.D_NGI	By Age/Sex: <15 Male	424	
C2.1.D_NGI	By Age/Sex: 15+ Female	7,388	
C2.1.D_NGI	By Age/Sex: 15+ Male	13,719	
C2.1.D_NGI	Sum of Age/Sex disaggregates	21,760	
C2.1.D_NGI	By Age: <15	672	
C2.1.D_NGI	By Age: 15+	21,088	
C2.1.D_NGI	Sum of Age disaggregates	21,760	
C2.1.D_NGI	By Sex: Female	14,143	
C2.1.D_NGI	By Sex: Male	7,617	
C2.1.D_NGI	Sum of Sex disaggregates	21,760	



C2.1.D_TA	By Age: <15	20	
C2.1.D_TA	By Age: 15+	630	
C2.1.D_TA	Sum of Age disaggregates	650	
C2.1.D_TA	By Sex: Female	228	
C2.1.D_TA	By Sex: Male	422	
C2.1.D_TA	Sum of Sex disaggregates	650	
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	20,000	
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	21,110	
FN_THER_DSD	Number of clinically malnourished PLHIV who		1,200
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,200	1,200
FN_THER_DSD	Aggregated Age: <18	400	400
FN_THER_DSD	Aggregated Age: 18+	800	800
FN_THER_DSD	Sum of Aggregated Age disaggregates	1,200	1,200
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,000	18,000
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	6	7
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4	4
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	260	292
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,140	11,408
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	280	315
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,320	5,985
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	540	607
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	15,460	17,393
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	16,000	18,000
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	16,450	18,450



TX_CURR_NGI	Aggregated Age/Sex: <1 Male	5	5
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	5	5
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	268	300
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	10,432	11,700
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	288	323
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	5,462	6,127
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	16,450	18,450
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	556	623
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	15,894	17,827
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	450	450
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8	8
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	292	292
TX_CURR_TA	Aggregated Age/Sex: <15 Female	8	8
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	142	142
TX_CURR_TA	Sum of Aggregated Age/Sex <15	16	16
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	434	434
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	450	450
TX_NEW_DSD	TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART)		2,300
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	3	3
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	25	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,642	1,511
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	25	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female 808		743
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,500	2,300
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,270	2,250
TX_RET_DSD	Total number of adults and children who	2,503	2,500



			· · · · · · · · · · · · · · · · · · ·
	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,222	2,250
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	53	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,450	2,500
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	39	
LAB_CAP_DSD	By Point-of-care testing sites	39	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	39	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	39	

Mechanism ID: 14156	TBD: Yes	
REDACTED		



# **Implementing Mechanism Details**

Mechanism ID: 14086	Mechanism Name: Research and Evaluation - USAID			
Funding Agency: USAID	Procurement Type: Cooperative Agreement			
Prime Partner Name: Management Systems Interna	ational			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
Total All Funding Sources: 32,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	32,000			

# Sub Partner Name(s)

(No data provided.)

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

# **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID:	14086		
Mechanism Name:	Research and Evaluation - USAID		
Prime Partner Name:	Management Systems International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Custom	Page 121 of 194 FACTS Info v3 8 15 8		



Governance and	HVSI	32,000	0
Systems	пузі	52,000	0

(No data provided.)

# Implementing Mechanism Details

Mechanism ID: 14048 Mechanism Name: Methadone Clinical S		
Funding Agency: HHS/SAMHSA	Procurement Type: Contract	
Prime Partner Name: Hennepin Faculty Associates-	Addiction Medicine Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: No		
G2G: No Managing Agency:		

Total All Funding Sources: 150,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	150,000

# Sub Partner Name(s)

(No data provided.)

#### **Cross-Cutting Budget Attribution(s)**

Human Resources for Health 150,000	Human Resources for Health	150,000
------------------------------------	----------------------------	---------

### **Key Issues**

(No data provided.)



# **Budget Code Information**

Mechanism ID:	14048		
Mechanism Name:	Methadone Clinical Support		
Prime Partner Name:	Hennepin Faculty Associates-Addiction Medicine Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	105,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	45,000	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 13942	Mechanism Name: Vietnam HIV-Addictions Technology Transfer Center (V-HATTC)	
Funding Agency: HHS/SAMHSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at	Los Angeles	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	
Total All Funding Sources: 350,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	350,000	

# Sub Partner Name(s)



Hanoi Medical University
--------------------------

### Cross-Cutting Budget Attribution(s)

Liuman Dessuress for Liestin	250.000
Human Resources for Health	350,000

#### **Key Issues**

(No data provided.)

# **Budget Code Information**

	13942 Vietnam HIV-Addictions University of California	••	enter (V-HATTC)
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	245,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	105,000	0

#### Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 13779	Mechanism Name: WHO
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	



G2G: No	Managing Agency:	
Total All Funding Sources: 90,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source Funding Amount		
GHP-State	90,000	

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Key Issues**

ΤВ

## **Budget Code Information**

Mechanism ID: Mechanism Name:	who			
Prime Partner Name: Strategic Area	Budget Code         Planned Amount         On Hold Amount			
Care	HVTB	60,000		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	30,000		0

### Implementing Mechanism Indicator Information

Custom 2015-03-30 12:28 EDT



(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 13759	Mechanism Name: Pathways for Participation	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Research Triangle Internationa	al	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	
Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	

### Sub Partner Name(s)

Care International	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Key Issues**

(No data provided.)

#### **Budget Code Information**

Mechanism ID: 13759 Mechanism Name: Pathways for Participation Prime Partner Name: Research Triangle International

Page 126 of 194



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

(No data provided.)

#### Implementing Mechanism Details

Mechanism ID: 13234	Mechanism Name: TB CARE - 1	
Funding Agency: USAID Procurement Type: Cooperative Agreem		
Prime Partner Name: KNCV Tuberculosis Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	1,000,000

## Sub Partner Name(s)

Management Sciences for Health World Health Organization
--

#### Cross-Cutting Budget Attribution(s)

	Human Resources for Health	400,000
--	----------------------------	---------



# Key Issues

ΤВ

# **Budget Code Information**

<b>V</b>			
Mechanism ID:	13234		
Mechanism Name:	TB CARE - 1		
Prime Partner Name:	KNCV Tuberculosis Fou	undation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,000,000	0

Indicator Number	Label	2014	2015
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	18	
SITE_SUPP	JPP By program area/support type: Lab Technical Assistance-only (TA)		19
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	19	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	18	
LAB_ACC_DSD By site support type: Technical Assistance-only (TA)		1	
LAB_ACC_DSD	Sum of Support Type disaggregates	19	
LAB_CAP_DSD	_DSD Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		19



LAB_CAP_DSD	By Point-of-care testing sites	19	19
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	19	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	19	19

# **Implementing Mechanism Details**

Mechanism ID: 13147	Mechanism Name: HIVQUAL		
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement		
Prime Partner Name: New York AIDS Institute			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		
Total All Funding Sources: 14,000	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 483,194			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	14,000		

### Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

|--|

### **Key Issues**

(No data provided.)

### **Budget Code Information**

Custom 2015-03-30 12:28 EDT



Mechanism ID: Mechanism Name:			
Prime Partner Name:	New York AIDS Institute	)	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	14,000	0

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 13131	Mechanism Name: I-TECH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washingto	on
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 200,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	200,000

### Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)



# **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID:	13131		
Mechanism Name:	I-TECH		
Prime Partner Name:	University of Washington	on	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

# **Implementing Mechanism Details**

Mechanism ID: 13073	Mechanism Name: Umbrella (HQ)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: World Health Organiz	zation
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	·
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 350,000	
FY 2013 Burn Rate: Redacted	

Funding Source	Funding Amount
GHP-State	0

### Sub Partner Name(s)



(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

#### Key Issues

ΤВ

#### **Budget Code Information**

Mechanism ID:	13073		
Mechanism Name:	Umbrella (HQ)		
Prime Partner Name:	World Health Organizat	ion	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13007	Mechanism Name: NTP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Vietnam National TB Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 380,000	Total Mechanism Pipeline: Redacted



Applied Pipeline Amount: 0 FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	380,000

# Sub Partner Name(s)

(No data provided.)

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

### **Key Issues**

(No data provided.)

# **Budget Code Information**

U			
Mechanism ID:	13007		
Mechanism Name:	NTP		
Prime Partner Name:	Vietnam National TB Pr	ogram	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	240,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	140,000	0

Indicator Number	Label	2014	2015	Planning Budget
Custom	Page 133 of 194	4	FACTS	S Info v3.8.15.8
2015-03-30 12:28 EI	Т			



				Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	4	8	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	4	6	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	4	6	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	4	6	Redacted

# Implementing Mechanism Details

Mechanism ID: 12909	Mechanism Name: PQM	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: U.S. Pharmacopeia		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 80,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	80,000

# Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

# Key Issues

Custom 2015-03-30 12:28 EDT



(No data provided.)

#### **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	PQM			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	IDUP	56,000		0
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	24,000		0

# Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12750	Mechanism Name: Food and Nutrition Technical Assistance (FANTA III)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	0	



Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Key Issues**

(No data provided.)

### **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	Food and Nutrition Technical Assistance (FANTA III)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

# Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12736	Mechanism Name: FIND	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Innovative New Diagnostics		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: No	Managing Agency:	

Total All Funding Sources: 315,000	Total Mechanism Pipeline: Redacted



Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	315,000	

# Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

(No data provided.)

### **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID:	12736		
Mechanism Name:	FIND		
Prime Partner Name:	Foundation for Innovati	ve New Diagnostics	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	315,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted



SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	45	45	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	45	45	Redacted
LAB_CAP_DSD	AB_CAP_DSD By clinical laboratories		45	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD By site support type: Technical Assistance-only (TA)		45	45	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	45	45	Redacted

# Implementing Mechanism Details

Mechanism ID: 12341	Mechanism Name: VNA
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Vietnam Nurses' Asso	pciation
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: Yes	Managing Agency: DOD
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 520,000	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount

GHP-State

# Sub Partner Name(s)

Ministry of Defense, Vietnam	

0



# Cross-Cutting Budget Attribution(s)

(No data provided.)

# **Key Issues**

Military Population TB

### **Budget Code Information**

Mechanism ID:			
Mechanism Name:	VNA		
Prime Partner Name:	Vietnam Nurses' Assoc	iation	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 11609	Mechanism Name: Ambassador"s Fund for HIV/AIDS Public Diplomacy		
Funding Agency: State/EAP	Procurement Type: USG Core		
Prime Partner Name: U.S. Department of State			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: No			
G2G: No	Managing Agency:		



Total All Funding Sources: 0	g Sources: 0 Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 100,000			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GHP-State	0		

#### Sub Partner Name(s)

(No data provided.)

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Key Issues**

(No data provided.)

### **Budget Code Information**

Mechanism ID: Mechanism Name:	11609 Ambassador''s Fund for	r HIV/AIDS Public Diplom	асу
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 11605	Mechanism Name: HQ Activities	
Funding Agency: HHS/CDC	Procurement Type: USG Core	



Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC) Agreement Start Date: Redacted Agreement End Date: Redacted TBD: No New Mechanism: No Global Fund / Multilateral Engagement: No G2G: No Managing Agency: Total All Funding Sources: 0 Total Mechanism Pipeline: Redacted Applied Pipeline Amount: 250,000 FY 2013 Burn Rate: Redacted **Funding Source Funding Amount** GHP-State 0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Key Issues**

(No data provided.)

### **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:	HQ Activities U.S. Department of Health and Human Services/Centers for Disease			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	



# **Implementing Mechanism Indicator Information**

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 10832	Mechanism Name: ASCP LAB			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: American Society of Clinical Pathology				
Agreement Start Date: Redacted	ate: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
Γ				
Total All Funding Sources: 210,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	210,000			

### Sub Partner Name(s)

(No data provided.)

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

# **Key Issues**

(No data provided.)

### **Budget Code Information**

Custom 2015-03-30 12:28 EDT



Mechanism ID: Mechanism Name:	ASCP LAB		
Strategic Area	American Society of Cli Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	210,000	0

(No data provided.)

#### Implementing Mechanism Details

echanism ID: 10831 Mechanism Name: CLSI LAB				
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Clinical and Laboratory Standards Institute				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
Total All Funding Sources: 240,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 0				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	240,000			

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



# **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID:	10831		
Mechanism Name:	CLSI LAB		
Prime Partner Name:	<b>Clinical and Laboratory</b>	Standards Institute	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and			

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	12	12	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	12	12	Redacted
LAB_CAP_DSD	By clinical laboratories	12	12	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	12	12	Redacted
LAB_CAP_DSD	Sum of Site Support Type	12	12	Redacted



disaggregates			
---------------	--	--	--

Mechanism ID: 10118 Mechanism Name: Department o Administration		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Vietnam Administration	for Medical Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 290,000	Total Mechanism Pipeline: Redacted	
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	

#### Sub Partner Name(s)

(No data provided.)

GHP-State

# Cross-Cutting Budget Attribution(s)

Human Resources for Health 50,000
-----------------------------------

290,000

### **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID: 10118



Mechanism Name: Prime Partner Name:	Department of Medical Administration Vietnam Administration for Medical Sciences			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HBHC	60,000		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	150,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	80,000	0	

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	270	300	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	20	30	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	20	30	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	20	30	Redacted



LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	270	300	Redacted
LAB_CAP_DSD	By clinical laboratories	270	300	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	270	300	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	270	300	Redacted

Mechanism ID: 10001	TBD: Yes	
REDACTED		

# **Implementing Mechanism Details**

Mechanism ID: 10000 Mechanism Name: HAIVN				
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Harvard Medical School of AIDS Initiative in Vietnam				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: No				
G2G: No	Managing Agency:			
Total All Funding Sources: 1,353,000	Total Mechanism Pipeline: Redacted			
Applied Pipeline Amount: 347,000				
FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	1,353,000			

# Sub Partner Name(s)

Custom 2015-03-30 12:28 EDT



(No data provided.)

### **Cross-Cutting Budget Attribution(s)**

Human Resources for Health	500,000
----------------------------	---------

# Key Issues

(No data provided.)

### **Budget Code Information**

Mechanism ID:	10000				
Mechanism Name:	e: HAIVN				
Prime Partner Name:	Name: Harvard Medical School of AIDS Initiative in Vietnam				
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	HVSI	200,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	OHSS	323,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Treatment	HTXS	680,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Treatment	PDTX	150,000	0		

# Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning
Custom	Page 148 of 194	Page 148 of 194		S Info v3.8.15.8

2015-03-30 12:28 EDT



				Budget Targets
C2.1.D_TA	By Age/Sex: <15 Female	960		Redacted
C2.1.D_TA	By Age/Sex: <15 Male	21,240		Redacted
C2.1.D_TA	By Age/Sex: 15+ Female	890		Redacted
C2.1.D_TA	By Age/Sex: 15+ Male	13,910		Redacted
C2.1.D_TA	Sum of Age/Sex disaggregates	37,000		Redacted
C2.1.D_TA	By Age: <15	1,850		Redacted
C2.1.D_TA	By Age: 15+	35,150		Redacted
C2.1.D_TA	Sum of Age disaggregates	37,000		Redacted
C2.1.D_TA	By Sex: Female	22,200		Redacted
C2.1.D_TA	By Sex: Male	14,800		Redacted
C2.1.D_TA	Sum of Sex disaggregates	37,000		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	32,000	37,000	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	830	960	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	19,970	23,090	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	770	890	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	10,430	12,060	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,600	1,850	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	30,400	35,150	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	32,000	37,000	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0	0	Redacted



Mechanism ID: 9999	Mechanism Name: MOLISA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Labor, In	valids and Social Affairs
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: Pf	R/SR
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted

FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Key Issues**

(No data provided.)

# **Budget Code Information**

Mechanism ID:	9999		
Mechanism Name:	MOLISA		
Prime Partner Name:	Ministry of Labor, Invali	ds and Social Affairs	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

# Implementing Mechanism Indicator Information

(No data provided.)

# Implementing Mechanism Details

Mechanism Name: PI
Procurement Type: Cooperative Agreement
Agreement End Date: Redacted
New Mechanism: No
Managing Agency: HHS/CDC

Total All Funding Sources: 400,000         Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 0		
FY 2013 Burn Rate: Redacted		
Funding Source	Funding Amount	
GHP-State	400,000	

# Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)		
Human Resources for Health	100,000	
Custom	Page 151 of 194	FACTS Info v3.8.15.8
2015-03-30 12:28 EDT		



# **Key Issues**

(No data provided.)

#### **Budget Code Information**

Budget Code Inform			
Mechanism ID:	9998		
Mechanism Name:	PI		
Prime Partner Name:	Pasteur Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	110,000	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	1	1	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	400	500	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	3	10	Redacted



	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3	10	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3	10	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	401	501	Redacted
LAB_CAP_DSD	By clinical laboratories	1	1	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	1	1	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	400	500	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	401	501	Redacted

Mechanism ID: 9977	Mechanism Name: NIHE	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Institute for Hygiene a	nd Epidemiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: No		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 350,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	



FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	350,000

# Sub Partner Name(s)

(No data provided.)

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

# **Key Issues**

(No data provided.)

## **Budget Code Information**

Budget Couc mem					
Mechanism ID: 9977					
Mechanism Name:	NIHE				
Prime Partner Name:	National Institute for Hygiene and Epidemiology				
Strategic Area	Budget Code Planned Amount On Hold Amount				
Governance and Systems	HLAB	200,000	0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount		
Governance and Systems	HVSI	150,000	0		

	Indicator Number	Label	2014	2015	Planning Budget
--	------------------	-------	------	------	--------------------



				Targets
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	0	0	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	400	600	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	400	600	Redacted
LAB_CAP_DSD	By clinical laboratories	400	600	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	400	600	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	400	600	Redacted

Mechanism ID: 9976	Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Vietnam	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: PR/SR	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 8,466,529	Total Mechanism Pipeline: Redacted		
Applied Pipeline Amount: 533,471			
FY 2013 Burn Rate: Redacted			
Funding Source	Funding Amount		
GAP	1,857,750		
GHP-State	6,608,779		



# Sub Partner Name(s)

Bach Mai Hospital	•	National Institute of Dermato-Venereology
National Institute of Infectious and Tropical Diseases	National Pediatrics Hospital	Vietnam National TB Program

# Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,500,000
Key Populations: MSM and TG	150,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	250,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

# Key Issues

ΤВ



# **Budget Code Information**

Mechanism ID: 9976 Mechanism Name: Vietnam Administration for HIV/AIDS Control (VAAC) Prime Partner Name: Ministry of Health, Vietnam			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,192,349	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	85,227	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	358,960	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	164,790	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	393,875	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	478,714	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	257,747	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,566,967	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	266,671	0

Approved



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	546,710	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	МТСТ	582,857	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,259,441	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	312,221	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	269	270	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	75	68	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	2	10	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	47	47	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	47	47	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	32	31	Redacted
SITE_SUPP	By program area/support type: PMTCT	0	1	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	31	28	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	635	625	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	735	725	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	315	368	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	315	308	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	320	257	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	635	625	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	315	368	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	647	680	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	750	790	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of	5	20	Redacted



	mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_TA	Number of HIV- positive pregnant		45	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	22	22	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	32	32	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	22	21	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	22	22	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of		31	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	32	32	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	235,000	213,000	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	235,000	213,000	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	255	295	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	480	440	Redacted



PMTCT_STAT_DS D	Sum of Positives Status disaggregates	735	735	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	240,000	235,000	Redacted
PMTCT_STAT_NG	Number of new ANC and L&D clients	240,000	235,000	Redacted
PMTCT_STAT_NG	By: Known positives at entry	260	315	Redacted
PMTCT_STAT_NG	By: Number of new positives identified	490	485	Redacted
PMTCT_STAT_NG	Sum of Positives Status disaggregates	750	800	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,000	22,000	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	5,000	22,000	Redacted
PMTCT_STAT_TA	By: Known positives at entry	5	20	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	10	45	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	15	65	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	4,500	5,870	Redacted
KP_MAT_DSD	Sex: Male	4,275	5,635	Redacted
KP_MAT_DSD	Sex: Female	225	235	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	4,500	5,870	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	19,435	19,703	Redacted
KP_PREV_DSD	By key population type: Males who	11,553	11,933	Redacted



inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)				
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		5,970	Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,200	1,800	Redacted
HTC_TST_DSD	Number of individuals who received		288,790	Redacted
HTC_TST_DSD	By Test Result: Negative	310,483	283,821	Redacted
HTC_TST_DSD	By Test Result: Positive	5,317	4,969	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	315,800	288,790	Redacted
HTC_TST_DSD	DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		515	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ		52,500	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	280	275	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	259,000	235,500	Redacted



	1			)
	PERMISSION ONLY: 15+ Female			
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	800	790	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	315,000	288,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	315,800	288,790	Redacted
HTC_TST_NGI	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	315,800	288,790	Redacted
HTC_TST_NGI	By Test Result: Negative	310,483	283,821	Redacted
HTC_TST_NGI	By Test Result: Positive	5,317	4,969	Redacted
HTC_TST_NGI	Sum of Test Result disaggregates	315,800	288,790	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	520	515	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	56,000	52,500	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	280	275	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	259,000	235,500	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	800	790	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	315,000	288,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	315,800	288,790	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,500		Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	27,868		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	930		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	16,612		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	870		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	9,456		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	27,868		Redacted
C2.1.D_DSD	By Age: <15	1,800		Redacted
C2.1.D_DSD	By Age: 15+	26,068		Redacted
C2.1.D_DSD	Sum of Age disaggregates	27,868		Redacted



			1	
C2.1.D_DSD	By Sex: Female	10,326		Redacted
C2.1.D_DSD	By Sex: Male	17,542		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	27,868		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	27,868		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	930		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	16,612		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	870		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	9,456		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	27,868		Redacted
C2.1.D_NGI	By Age: <15	1,800		Redacted
C2.1.D_NGI	By Age: 15+	26,068		Redacted
C2.1.D_NGI	Sum of Age disaggregates	27,868		Redacted
C2.1.D_NGI	By Sex: Female	10,326		Redacted
C2.1.D_NGI	By Sex: Male	17,542		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	27,868		Redacted
C2.4.D_DSD	Number of HIV-positive patients who were screened for TB in HIV care or treatment setting	23,690		Redacted
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	27,868		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	780	780	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	735	735	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,200	22,470	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	30	0	Redacted



				1
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	30	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	990	1,130	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,140	13,800	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	860	970	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,210	6,570	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,850	2,100	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	18,350	20,370	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	20,200	22,470	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	20,200	22,470	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	30	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	30	0	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	990	1,130	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	12,140	13,800	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	860	970	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	6,210	6,570	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	20,200	22,470	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,850	2,100	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	18,350	20,370	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,150	3,340	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	25	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	125	120	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,820	1,950	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	25	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	125	120	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+	1,080	1,150	Redacted



	Female			
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,150	3,340	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,540	3,470	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,920	3,775	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	250	255	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,290	3,215	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	270	275	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,650	3,500	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing	28	28	Redacted



	facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	28	28	Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	28	28	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	92	97	Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	92	97	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	92	97	Redacted

Mechanism ID: 9974	Mechanism Name: HCMC PAC	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ho Chi Minh City Provin	cial AIDS Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: PR/SF	2	
G2G: Yes	Managing Agency: HHS/CDC	
Total All Funding Sources: 2,738,000	Total Mechanism Pipeline: Redacted	

Applied Pipeline Amount: 762,000						
FY 2013 Burn Rate: Redacted						
Funding Source	Funding Amount					
GHP-State	2,738,000					

### Sub Partner Name(s)

(No data provided.)



# Cross-Cutting Budget Attribution(s)

Human Resources for Health	750,000
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	80,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Education	75,000
Condom procurement	85,000

# Key Issues

ΤВ



Budget Code Inform	ation					
Mechanism ID:	9974					
Mechanism Name:						
Prime Partner Name:	Prime Partner Name: Ho Chi Minh City Provincial AIDS Committee					
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	НВНС	557,080	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	НУТВ	100,174	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	PDCS	17,599	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	HLAB	143,378	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Governance and Systems	HVSI	111,226	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	НУСТ	237,994	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	HVOP	93,687	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	IDUP	93,481	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Prevention	MTCT	154,631	0			

Approved



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,151,756	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	76,994	0

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	Number of unique sites supported by PEPFAR	169	153	Redacted
SITE_SUPP	By program area/support type: HTC Direct Service Delivery (DSD)	9	5	Redacted
SITE_SUPP	By program area/support type: HTC Technical Assistance-only (TA)	2	9	Redacted
SITE_SUPP	By program area/support type: Treatment Direct Service Delivery (DSD)	12	12	Redacted
SITE_SUPP	By program area/support type: Treatment Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Care and Support Direct Service Delivery (DSD)	12	12	Redacted
SITE_SUPP	By program area/support type: Care and Support Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: PMTCT Direct Service Delivery (DSD)	52	18	Redacted
SITE_SUPP	By program area/support type: PMTCT	4	38	Redacted



	Technical Assistance-only (TA)			
SITE_SUPP	By program area/support type: TB/HIV Direct Service Delivery (DSD)	25	25	Redacted
SITE_SUPP	By program area/support type: TB/HIV Technical Assistance-only (TA)	0	0	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Direct Service Delivery (DSD)	13	11	Redacted
SITE_SUPP	By program area/support type: Key Populations Prevention Technical Assistance-only (TA)	0	2	Redacted
SITE_SUPP	By program area/support type: OVC Direct Service Delivery (DSD)	3	0	Redacted
SITE_SUPP	By program area/support type: OVC Technical Assistance-only (TA)	21	0	Redacted
SITE_SUPP	By program area/support type: Lab Direct Service Delivery (DSD)	16	21	Redacted
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	0	0	Redacted
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	580	610	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	640	640	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	350	610	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	190	450	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	160	160	Redacted



PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	70	0	Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	160	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	580	610	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	350	610	Redacted
PMTCT_ARV_NGI	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	580	610	Redacted
PMTCT_ARV_NGI	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	640	640	Redacted
PMTCT_ARV_NGI	Life-long ART (including Option B+)	350	610	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	190	450	Redacted
PMTCT_ARV_NGI	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	160	160	Redacted
PMTCT_ARV_NGI	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	70	0	Redacted
PMTCT_ARV_NGI	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	160	0	Redacted
PMTCT_ARV_NGI	Single-dose nevirapine (with or without tail)	0	0	Redacted



PMTCT_ARV_NGI	Sum of Regimen disaggregates	580	610	Redacted
PMTCT_ARV_NGI	Sum of New and Current disaggregates	350	610	Redacted
PMTCT_SITE	Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	12	16	Redacted
PMTCT_SITE	Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	17	17	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	12	16	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women	0	0	Redacted
PMTCT_SITE	Sum of Numerator Support Type disaggregates	12	16	Redacted
PMTCT_SITE	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	17	17	Redacted
PMTCT_SITE	By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services)	0	0	Redacted
PMTCT_SITE	Sum of Denominator Support Type disaggregates	17	17	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	115,000	80,000	Redacted



	results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	120,000	82,000	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	480	480	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	160	160	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	640	640	Redacted
PMTCT_STAT_NG I	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	115,000	80,000	Redacted
PMTCT_STAT_NG I	Number of new ANC and L&D clients	120,000	82,000	Redacted
PMTCT_STAT_NG I	By: Known positives at entry	480	480	Redacted
PMTCT_STAT_NG I	By: Number of new positives identified	160	160	Redacted
PMTCT_STAT_NG I	Sum of Positives Status disaggregates	640	640	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,000	65,000	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	33,000	71,000	Redacted
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	1,128	1,460	Redacted
KP_MAT_DSD	Sex: Male	1,024	1,250	Redacted
KP_MAT_DSD	Sex: Female	104	210	Redacted
KP_MAT_DSD	Sum of Sex disaggregates	1,128	1,460	Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level	14,091	16,448	Redacted



	HIV preventive interventions that are			
	based on evidence and/or meet the			
	minimum standards required			
	By key population type: Female sex			
	workers (FSW) (Numerator: Number of			
	key populations reached with individual			
KP_PREV_DSD	and/or small group level HIV preventive	4,040	4,630	Redacted
	interventions that are based on			
	evidence and/or meet the minimum			
	standards required)			
	By key population type: Males who			
	inject drugs ( Male PWID) (Numerator:			
	Number of key populations reached			
KP PREV DSD	with individual and/or small group level	4,530	5,400	Redacted
	HIV preventive interventions that are	,		
	based on evidence and/or meet the			
	minimum standards required)			
	By key population type: Females who			
	inject drugs (Female PWID)			
	(Numerator: Number of key populations			
	reached with individual and/or small			
KP_PREV_DSD	group level HIV preventive	321	418	Redacted
	interventions that are based on			
	evidence and/or meet the minimum			
	standards required)			
	By key population type: Men who have			
	sex with men/Transgender (MSM/TG)			
	(Numerator: Number of key populations			
	reached with individual and/or small			
KP_PREV_DSD	group level HIV preventive	5,200	6,000	Redacted
	interventions that are based on			
	evidence and/or meet the minimum			
	standards required)			
	Number of key populations reached			
KP_PREV_TA		3 105	4 000	Redacted
	with individual and/or small group level	3,195	4,000	Neudoleu
	HIV preventive interventions that are			



	based on evidence and/or meet the			
	minimum standards required			
KP_PREV_TA	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	145		Redacted
KP_PREV_TA	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50		Redacted
KP_PREV_TA	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,000	4,000	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	142,160	101,580	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	370	380	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,720	15,080	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	200	200	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ	122,870	85,920	Redacted



	PERMISSION ONLY: 15+ Female			
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	570	580	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	141,590	101,000	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	142,160	101,580	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Male	370	380	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Male	18,720	15,080	Redacted
HTC_TST_NGI	Aggregated Age/sex: <15 Female	200	200	Redacted
HTC_TST_NGI	Aggregated Age/sex: 15+ Female	122,870	85,920	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex <15	570	580	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex 15+	141,590	101,000	Redacted
HTC_TST_NGI	Sum of Aggregated Age/Sex disaggregates	142,160	101,580	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,000	76,800	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,100	8,360	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30,900	68,440	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	30,900	68,440	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,100	8,360	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	33,000	76,800	Redacted
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	670	0	Redacted
OVC_SERV_DSD	Sex: Male	360	0	Redacted
OVC_SERV_DSD	Sex: Female	310	0	Redacted
OVC_SERV_DSD	Sum of Sex disaggregates	670	0	Redacted
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,130	0	Redacted



OVC_SERV_TA	Sex: Male	2,210	0	Redacted
OVC_SERV_TA	Sex: Female	1,920	0	Redacted
OVC_SERV_TA	Sum of Sex disaggregates	4,130	0	Redacted
C2.1.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	17,730		Redacted
C2.1.D_DSD	By Age/Sex: <15 Female	640		Redacted
C2.1.D_DSD	By Age/Sex: <15 Male	690		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Female	5,565		Redacted
C2.1.D_DSD	By Age/Sex: 15+ Male	10,835		Redacted
C2.1.D_DSD	Sum of Age/Sex disaggregates	17,730		Redacted
C2.1.D_DSD	By Age: <15	1,330		Redacted
C2.1.D_DSD	By Age: 15+	16,400		Redacted
C2.1.D_DSD	Sum of Age disaggregates	17,730		Redacted
C2.1.D_DSD	By Sex: Female	11,525		Redacted
C2.1.D_DSD	By Sex: Male	6,205		Redacted
C2.1.D_DSD	Sum of Sex disaggregates	17,730		Redacted
C2.1.D_NGI	Number of HIV-positive individuals receiving a minimum of one clinical service	17,730		Redacted
C2.1.D_NGI	By Age/Sex: <15 Female	640		Redacted
C2.1.D_NGI	By Age/Sex: <15 Male	690		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Female	5,565		Redacted
C2.1.D_NGI	By Age/Sex: 15+ Male	10,835		Redacted
C2.1.D_NGI	Sum of Age/Sex disaggregates	17,730		Redacted
C2.1.D_NGI	By Age: <15	1,330		Redacted
C2.1.D_NGI	By Age: 15+	16,400		Redacted
C2.1.D_NGI	Sum of Age disaggregates	17,730		Redacted
C2.1.D_NGI	By Sex: Female	11,525		Redacted
C2.1.D_NGI	By Sex: Male	6,205		Redacted
C2.1.D_NGI	Sum of Sex disaggregates	17,730		Redacted
C2.4.D_DSD	Number of HIV-positive patients who	17,250		Redacted



	were screened for TB in HIV care or			
	treatment setting			
C2.4.D_DSD	Number of HIV-positive individuals receiving a minimum of one clinical service	17,730		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	570	580	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	640	640	Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	530	540	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	40	40	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	570	580	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	12	10	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	13,290	13,621	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	8	8	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	7	7	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	600	630	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,990	8,121	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	555	585	Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,145	4,285	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,155	1,215	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	12,135	12,406	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	13,290	13,621	Redacted
TX_CURR_NGI	Number of adults and children receiving antiretroviral therapy (ART)	13,290	13,621	Redacted



r	1		1	L.
TX_CURR_NGI	Aggregated Age/Sex: <1 Male	8	8	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <1 Female	7	7	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Male	600	630	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Male	7,990	8,121	Redacted
TX_CURR_NGI	Aggregated Age/Sex: <15 Female	555	585	Redacted
TX_CURR_NGI	Aggregated Age/Sex: 15+ Female	4,145	4,285	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex disaggregates	13,290	13,621	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex <15	1,155	1,215	Redacted
TX_CURR_NGI	Sum of Aggregated Age/Sex 15+	12,135	12,406	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	160	140	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	3	3	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2	2	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	90	80	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	0	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	70	60	Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	0	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	160	140	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	0	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	160	140	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,760	1,925	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	8	8	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	60	60	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,033	1,137	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	7	7	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	50	50	Redacted

Approved



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	617	678	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,760	1,925	Redacted
TX_NEW_DSD	Pregnancy status	120	200	Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	139	139	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,165	1,554	Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months DSD prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		153	Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,387	1,850	Redacted
TX_RET_DSD	DSD Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		160	Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the	120	200	Redacted



	12 months prior to the beginning of the reporting period, including those who			
have died, those who have stopped ART, and those lost to follow-up)				
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	16	21	Redacted
LAB_CAP_DSD By clinical laboratories		16	21	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	16	21	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	16	21	Redacted

# Implementing Mechanism Details

Mechanism ID: 9973	Mechanism Name: HSPH
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hanoi School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 278,500	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 36,500	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	278,500

# Sub Partner Name(s)

(No data provided.)

# Cross-Cutting Budget Attribution(s)

Human Resources for Health	225,000
----------------------------	---------



# **Key Issues**

(No data provided.)

## **Budget Code Information**

Budget Oode miering				
Mechanism ID:	9973			
Mechanism Name:	HSPH			
Prime Partner Name:	Hanoi School of Public	Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	105,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	173,500	0	

# Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	25	25	Redacted
HRH_PRE	By Graduates: Other	25	25	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	25	25	Redacted



#### **Implementing Mechanism Details**

lechanism ID: 9972 Mechanism Name: APHL LAB	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health	Laboratories
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:
Total All Funding Sources: 210,000	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	
FY 2013 Burn Rate: Redacted	
Funding Source	Funding Amount
GHP-State	210,000

#### Sub Partner Name(s)

(No data provided.)

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Key Issues**

(No data provided.)

## **Budget Code Information**

Mechanism ID:	9972			
Mechanism Name:	APHL LAB			
Prime Partner Name:	Association of Public H	ealth Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Governance and	HLAB	210,000	0
Systems	HLAD	210,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2014	2015	Planning Budget Targets
SITE_SUPP	By program area/support type: Lab Technical Assistance-only (TA)	17	17	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	17	17	Redacted
LAB_CAP_DSD	By clinical laboratories	17	17	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	0	0	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	0	Redacted
LAB_CAP_DSD	AB_CAP_DSD By site support type: Technical Assistance-only (TA)		17	Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17	17	Redacted

# Implementing Mechanism Details

Mechanism ID: 7348	Mechanism Name: UNAIDS
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Joint Pr	rogramme on HIV/AIDS
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: No	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: Redacted
Applied Pipeline Amount: 0	



FY 2013 Burn Rate: Redacted				
Funding Source	Funding Amount			
GHP-State	0			

#### Sub Partner Name(s)

(No data provided.)

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

#### **Key Issues**

(No data provided.)

#### **Budget Code Information**

Mechanism ID:	7348						
Mechanism Name:	UNAIDS						
Prime Partner Name:	ne Partner Name: United Nations Joint Programme on HIV/AIDS						
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Governance and							

#### **Implementing Mechanism Indicator Information**

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 7345	Mechanism Name: SCMS			
Funding Agency: USAID	Procurement Type: Contract			
Prime Partner Name: Partnership for Supply Chain Management				



Agreement Start Date: Redacted Agreement End Date: Redacted					
TBD: No	New Mechanism: No				
Global Fund / Multilateral Engagement: No					
G2G: No	Managing Agency:				
Total All Funding Sources: 12,000,000	Total Mechanism Pipeline: Redacted				
Applied Pipeline Amount: 500,000					
FY 2013 Burn Rate: Redacted					
Funding Source	Funding Amount				
GHP-State	12,000,000				

# Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

#### **Key Issues**

(No data provided.)

## **Budget Code Information**

Mechanism ID: Mechanism Name: Prime Partner Name:		Chain Management	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	1,400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	10,600,000	0



# Implementing Mechanism Indicator Information

(No data provided.)



# Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		224,251		Redacted	224,251	0
ICASS		715,783		Redacted	715,783	0
Management Meetings/Profes sional Developement		235,320		Redacted	235,320	0
Non-ICASS Administrative Costs		290,724		Redacted	290,724	0
Staff Program Travel		366,240		Redacted	366,240	0
USG Staff Salaries and Benefits		2,524,090		Redacted	2,524,090	0
Total	0	4,356,408	0	0	4,356,408	0

## U.S. Agency for International Development Other Costs Details

Category	ltem	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Computers/IT Services		GHP-State		Redacted	224,251	0
ICASS		GHP-State		Redacted	715,783	0
Management		GHP-State		Redacted	235,320	0



Meetings/Prof				
essional				
Developement				
Non-ICASS		Redacted		
Administrative	GHP-State		290,724	0
Costs				

# U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		Redacted	0	40,000
ICASS		0		Redacted	0	120,000
Management Meetings/Profes sional Developement		0		Redacted	0	100,000
Non-ICASS Administrative Costs		0		Redacted	0	70,000
Staff Program Travel		0		Redacted	0	80,000
USG Staff Salaries and Benefits		0		Redacted	0	250,000
Total	0	0	0	0	0	660,000

## U.S. Department of Defense Other Costs Details

Category	ltem	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
----------	------	-------------------	-------------	------------------------------------	--------	---------------------



Computers/IT Services	GHP-State	Redacted	0	40,000
ICASS	GHP-State	Redacted	0	120,000
Management Meetings/Prof essional Developement	GHP-State	Redacted	0	100,000
Non-ICASS Administrative Costs	GHP-State	Redacted	0	70,000

# U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		0		Redacted	0	0
Computers/IT Services		0		Redacted	0	416,642
ICASS		0		Redacted	0	1,886,938
Institutional Contractors	0	0	0	Redacted	0	420,748
Management Meetings/Profes sional Developement		0		Redacted	0	200,000
Non-ICASS Administrative Costs		0		Redacted	0	337,000
Staff Program Travel		0		Redacted	0	320,000



Total	0	0	0	0	0	6,234,398
Benefits						
Salaries and	0	0			0	2,653,070
USG Staff				Redacted		

# U.S. Department of Health and Human Services/Centers for Disease Control and Prevention Other Costs Details

Category	ltem	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	0	0
Computers/IT Services		GHP-State		Redacted	0	416,642
ICASS		GHP-State		Redacted	0	1,886,938
Management Meetings/Prof essional Developement		GHP-State		Redacted	0	200,000
Non-ICASS Administrative Costs		GHP-State		Redacted	0	337,000

# U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		20,854		Redacted	20,854	0
Computers/IT Services		15,000		Redacted	15,000	0

Custom 2015-03-30 12:28 EDT



Total	0	700,000	0	0	700,000	0
Benefits						
Salaries and		282,645			282,645	0
USG Staff				Redacted		
Staff Program Travel		237,355		Redacted	237,355	0
Administrative Costs		50,000			50,000	0
Non-ICASS				Redacted		
Developement						
Meetings/Profes sional		19,146			19,146	0
Management				Redacted		
ICASS		75,000		Redacted	75,000	0

# U.S. Department of Health and Human Services/Substance Abuse and Mental Health Services Administration Other Costs Details

Category	ltem	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Capital Security Cost Sharing		GHP-State		Redacted	20,854	0
Computers/IT Services		GHP-State		Redacted	15,000	0
ICASS		GHP-State		Redacted	75,000	0
Management Meetings/Prof essional Developement		GHP-State		Redacted	19,146	0
Non-ICASS Administrative Costs		GHP-State		Redacted	50,000	0



## U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Planned Amount As Of Last Q1	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS				Redacted		
Administrative Costs		0			0	60,000
USG Staff				Redacted		
Salaries and		0			0	0
Benefits						
Total	0	0	0	0	0	60,000

# U.S. Department of State Other Costs Details

Category	ltem	Funding Source	Description	Planned Amount As Of Last Q1	Amount	Applied Pipeline
Non-ICASS				Redacted		
Administrative		GHP-State			0	60,000
Costs						